

Article

Not peer-reviewed version

Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep-Learning-Enhanced T2-EPI-FLAIR Sequence

<u>Martin Schuhholz</u>*, <u>Christer Ruff</u>, Eva Bürkle, <u>Thorsten Feiweier</u>, Bryan Clifford, <u>Markus Kowarik</u>, Benjamin Bender

Posted Date: 24 June 2024

doi: 10.20944/preprints202406.1633.v1

Keywords: ultrafast brain MRI; multi-shot EPI; ultrafast FLAIR; deep learning; image acceleration; image enhancement; multiple sclerosis; inflammatory brain lesions



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep-Learning-Enhanced T2-EPI-FLAIR Sequence

Martin Schuhholz ^{1,*}, Christer Ruff ¹, Eva Bürkle ¹, Thorsten Feiweier ², Bryan Clifford ³, Markus Kowarik ⁴ and Benjamin Bender ¹

- ¹ Department of Diagnostic and Interventional Neuroradiology, Eberhard Karls University, University Hospital, Tuebingen, Germany; martin.schuhholz@gmail.com (M.S.); christer.ruff@med.uni-tuebingen.de (C.R.); eva.buerkle@med.uni-tuebingen.de (E.B.); benjamin.bender@med.uni-tuebingen.de (B.B.)
- ² Siemens Healthineers AG, Erlangen, Germany; thorsten.feiweier@siemens-healthineers.com
- ³ Siemens Medical Solutions USA, Boston, Massachusetts, United States of America; bryan.clifford@siemens-healthineers.com
- Department of Neurology and Stroke, Neurological Clinic, Eberhard Karls University, University Hospital, Tuebingen, Germany; markus.kowarik@med.uni-tuebingen.de
- * Correspondence: martin.schuhholz@gmail.com

Abstract: Magnetic resonance (MR) image acquisitions are usually time-consuming, limiting utilization in neuroimaging. For multiple sclerosis (MS) patients, MR imaging plays a major role in drug therapy decisionmaking. The purpose of this study was to evaluate whether an ultrafast, T2-weighted (T2w), deep-learningenhanced (DL), echo-planar-imaging-based (EPI) fluid-attenuated inversion recovery (FLAIR) sequence (FLAIRuf) that has been targeting neurological emergencies so far might even be an option to detect MS lesions of the brain compared to conventional FLAIR sequences. Therefore, 17 MS patients were enrolled prospectively in this exploratory study. Standard MR protocols and ultrafast acquisitions were conducted at 3 tesla (T), including three-dimensional (3D)-FLAIR, turbo/fast spin echo (TSE)-FLAIR, and FLAIRuf. Inflammatory lesions were grouped by size and location. Lesion conspicuity and image quality were rated on an ordinal fivepoint Likert scale, and lesion detection rates were calculated. Statistical analyses were performed to compare results. Altogether, 568 different lesions were found. Data indicated no significant differences in lesion detection (sensitivity and positive predictive value [PPV]) between FLAIRUF and axially reconstructed 3D-FLAIR (lesion size ≥ 3 mm × ≥ 2 mm) and no differences in sensitivity between FLAIR_{UF} and TSE-FLAIR (lesion size ≥ 3 mm total). Lesion conspicuity in FLAIRuF was similar in all brain regions except for superior conspicuity in the occipital lobe and inferior conspicuity in central brain regions. Further findings include locationdependent limitations of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) as well as artifacts such as spatial distortions in FLAIRuf. In conclusion, FLAIRuf could potentially be an expedient alternative to conventional methods for brain imaging in MS patients since the acquisition can be performed in a fraction of time while maintaining good image quality.

Keywords: ultrafast brain MRI; multi-shot EPI; ultrafast FLAIR; deep learning; image acceleration; image enhancement; multiple sclerosis; inflammatory brain lesions

1. Introduction

Echo-planar imaging (EPI) represents a very fast acquisition technique in magnetic resonance imaging (MRI). It was first described by Mansfield in 1977 [1] and has since been refined. In [2] Poustchi-Amin et al. reviewed the main principles of EPI: to reduce the number of excitation pulses, thus reducing the number of repetition time (TR) periods by acquiring multiple k-space lines per shot, i.e., during a repetition period. It can be performed using only one shot (single-shot EPI), which means that k-space is filled completely following one excitation, or otherwise using multiple shots (multi-shot EPI), i.e., a particular fraction (obeying a regular sampling pattern along the phase-

encoding direction) of k-space is filled with data within each TR period. This can be achieved by generating repetitive echo train signals. Apart from diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), functional MRI (fMRI), and occasionally T2*-weighted (T2*w) imaging [3], EPI has not been integrated in other routine brain MRI sequences such as fluid-attenuated inversion recovery (FLAIR) for the assessment of inflammatory lesions due to drawbacks in terms of image quality and artifacts.

Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS). Neuro-inflammation thereby results in demyelination and axonal damage with reactive gliosis and lesion formation leading to clinical disability progression [4]. MS is the most frequent demyelinating disease worldwide, with the highest prevalence levels in Europe and North America (over 100/100,000 inhabitants) [5]. Relapsing-remitting multiple sclerosis (RRMS) is the most frequent initial course of MS, and women are affected two to three times (or more) as often as men [5]. According to the McDonald criteria and its later revisions, dissemination of CNS lesions in time and space needs to be fulfilled for diagnosis, thus inevitably requiring appropriate MRI examinations [6–9]. Again, the diagnosis of MS entails further scans for disease activity and treatment monitoring [10]. For this purpose, a FLAIR sequence is an essential tool for cerebral imaging, and the availability of a fast imaging technique would be relevant in that context, given the high prevalence of this disease and the corresponding costs.

In 1999, Filippi et al. analyzed MS lesion detectability in ultrafast EPI-FLAIR images compared to conventional fast spin-echo FLAIR images. They observed similar lesion numbers for lesions that were greater than ten millimeters in long-axis diameter. Detection of smaller lesions proved inferior using EPI-FLAIR sequences [11]. Owing to specificity reasons, there has been support for a size threshold of white matter lesions to allow the diagnosis of MS [12,13]. According to the McDonald criteria, hyperintense areas are referred to as lesions if they are greater than three millimeters in long axis [6–9]. Grahl et al. recently reviewed those stipulations about a lesion size threshold and confirmed three millimeters to be a reasonable threshold to account for diagnostic criteria in MS for three-dimensional (3D) MRI acquisitions at 3 tesla (T) [14]. However, the effectiveness of EPI-FLAIR sequences has been far from meeting those targets and has therefore not been a suitable option for routine MRI scans.

In recent years, significant advancements in machine learning have gained great attention in the field of medical imaging [15]. Applied to image reconstruction, these deep learning (DL) techniques provide an improved trade-off between speed, resolution and signal-to-noise ratio (SNR), and often enable significant reductions in scan times when combined with (highly) accelerated conventional techniques such as parallel imaging (PI) [16–19]. Alternative methods include compressed sensing (CS) [20–23], simultaneous multislice (SMS) imaging (also known as multiband imaging) [24–28], iterative denoising (ID) [29,30] and synthetic MRI [31–38].

The acceleration provided by these techniques has redoubled interest in further investigations. Particularly, the integration of several of these methods with EPI-based imaging has led to the development of ultrafast multi-contrast protocols, providing all contrasts required in an emergency setting (T1, T2, T2*, T2-FLAIR, DWI) [39–46]. There is also an approach to incorporate various contrasts in one sequence [47–52]. So far, these methods have not been targeting clinical applications that rely to some extent on high resolution data. Also, current research that focuses on EPI-FLAIR in particular is limited and primarily addresses stroke patients and pediatric patients [53–56]. In-depth evaluations of MS patient brain images that were acquired using DL-enhanced EPI-FLAIR acquisition techniques have not been conducted to date to our knowledge. Although 3D-FLAIR is clearly given preference over 2D-FLAIR for diagnosis and monitoring of MS [57,58], the purpose of this part of our study was to evaluate whether a 2D ultrafast DL-enhanced EPI-FLAIR (FLAIRuf) sequence of the brain could be an adequate alternative to conventional FLAIR scans.

2. Materials and Methods

2.1. Study Design

This prospective, exploratory study was approved by the institutional review board (Project ID 031/2021BO2). We adhered to the 1964 Declaration of Helsinki and its later amendments. Inclusion criteria were adulthood (≥ 18 years), a routine MRI examination to be carried out on the 3 T MAGNETOM Vida (Siemens Healthineers AG, Forchheim, Germany) scanner, and at least three of the following five MRI contrasts to be conducted: T1-weighted (T1w), T2w, T2*w, DWI, or T2w FLAIR. Moreover, a criterion for allocation to the MS study group was having MS according to the McDonald criteria (2017) [9]. Exclusion criteria were lack of capacity to consent, missing written informed consent, acute stroke in the lysis time window, or general MRI contraindications, such as non-MRI compliant implants or severe claustrophobia. As can be seen in Figure 1, 17 MS patients underwent 3 T MRI scans of the brain between May 2021 and March 2022. For details on patient characteristics, see Table 1. All eligible patients gave written informed consent to participate in this voluntary study.




Figure 1. Flowchart of study participants. Note. MRI = magnetic resonance imaging; MS = multiple sclerosis.

Table 1. Patient characteristics.

Characteristics	Values
Number of patients	17
Mean age ± standard deviation	on 33 ± 10 years
Median age (range)	29 (21 – 60) years
Distribution between sexes	71% male (n = 12), 29% female (n = 5)

Note. One patent underwent a second follow-up MRI examination six months later during the investigation period and is included twice. Years and percentages are rounded to the whole numbers.

2.2. Imaging Protocol and Image Acquisition

All examinations were conducted using a 3 T MRI scanner (see Section 2.1). We used a 20-channel head and neck coil and applied our standard protocol for patients with MS, incorporating the following contrasts: 3D T1 magnetization prepared rapid gradient echo (MPRAGE), contrast-enhanced 3D T1-MPRAGE, contrast-enhanced axial T1 turbo/fast spin echo (TSE), infratentorial axial T2-TSE, axial DWI, 3D double inversion recovery (DIR), and 3D-T2-FLAIR (FLAIR3D). In three patients, an axial standard T2-TSE-FLAIR (FLAIRTSE) sequence was added as well. Additionally, we acquired the ultrafast axial T2w FLAIRUF research sequence in all patients, along with other ultrafast sequences that are not in the scope of this article (i.e., two native axial T1w contrasts, two contrast-enhanced axial T1w contrasts, axial DWI, and an axial sequence providing a T2*w and a T2w contrast). All native sequences were acquired prior to the contrast agent application, and the standard protocol sequences were acquired in advance of the ultrafast sequences. The acquisition parameters for all three T2w FLAIR sequences (i.e., FLAIRUF, FLAIRTSE, and FLAIR3D) are given in Table 2. By

using the FLAIR_{UF} sequence, which takes 0:51 min, the acquisition time can be reduced to almost a sixth of the time required for the FLAIR_{3D} sequence (4:57 min) and nearly a third of the time required for the FLAIR_{TSE} sequence (2:22 min).

After acquisition of the data and extraction of relevant clinical data, imaging data were deidentified using RSNA Clinical Trial Processor (CTP) software (RSNA CTP Java Version 1.8, Radiological Society of North America, Oak Brook, IL, USA) for further evaluation within this trial.

Parameter **FLAIR**UF FLAIR3D **FLAIR**TSE Orientation Axial Axial Sequence type Multi-shot EPI TSE **SPACE** TR (ms) 8000 8800 5000 TE (ms) 88 87 386 TI (ms) 2372 2480 1800 Flip angle (°) 180 150 120 (VFA) Voxel size (mm) $0.9 \times 0.9 \times 4$ $0.7 \times 0.7 \times 40.5 \times 0.5 \times 0.9$ 1 0.8 0 Gap between slices (mm) $R \rightarrow L$ $P \rightarrow A$ Phase encoding direction $A \rightarrow P$ Acceleration mode DL-based **GRAPPA GRAPPA** Acceleration factor 2 2 2 In-plane FOV (read × phase; mm) 230×230 230×187 256 × 256 1 32 36 192 Number of slices 0:51 2:22 4:57 Time of acquisition (min:s)

Table 2. MRI acquisition parameters.

Note. FLAIR = fluid-attenuated inversion recovery; FLAIR $_{UF}$ = ultrafast FLAIR sequence; FLAIR $_{SE}$ = turbo/fast spin echo FLAIR sequence; FLAIR $_{SD}$ = three-dimensional FLAIR sequence; TR = repetition time; TE = echo time; TI = inversion time; FOV = field-of-view; EPI = echo-planar-imaging; TSE = turbo/fast spin echo; SPACE = sampling perfection with application optimized contrasts using different flip angle evolution; VFA = variable flip angles; A = anterior; P = posterior; R = right; L = left; DL =deep learning; GRAPPA = generalized autocalibrating partial parallel acquisition. 1 Values refer to the sagittal orientation. Slice thickness of the axially reconstructed images used for side-by-side comparisons (FLAIR $_{SDa}$) = 3 mm.

2.3. FLAIRuf Sequence

The FLAIRUF sequence examined in this study was a T2w inversion-recovery double-shot spin-echo EPI sequence, i.e., k-space data for each image were acquired in two shots with interleaved phase-encoding patterns. Each shot consisted of a spin-echo inversion recovery excitation module followed by a 64-echo readout train. In all three FLAIR sequences (FLAIRUF, FLAIRTSE, and FLAIR3D), the PI acceleration factor was two.

In order to alleviate the deterioration in image quality caused by the above-mentioned acceleration techniques, the FLAIRUF sequence has several novel features. One of them is a DL-enhanced processing technique that employs a machine-learning-based reconstruction to decrease image noise and residual aliasing [43–45,59]. It was trained on data acquired with a 20-channel head matrix coil at 3 T [43,44]. However, the clinical patient images included in our study were not part of the training data. The reconstruction method requires coil sensitivity maps based on the eigenvector-based iterative self-consistent parallel imaging reconstruction technique (ESPIRiT) [60]. Those maps are calculated using fast low angle shot (FLASH)-based autocalibration scans acquired prior to the slice scans. Furthermore, geometric coil compression was utilized for improving reconstruction performance, reducing reconstruction times [61]. Another novel feature implemented is magnetization transfer (MT) preparation to improve tissue contrast, as described in [62]. In addition, the FLAIRUF sequence utilizes the following techniques to improve image quality, amongst others: Field map based geometric distortion correction [63,64], phase correction scans to mitigate residual Nyquist ghosting, flow attenuation gradients to weaken signals from flowing or pulsating fluids, and automated interleaving of inversion and acquisition modules to further optimize the scan efficiency.

2.4. Image Evaluation

Inflammatory lesions and image quality were evaluated by one reader (M.S.), and all ratings were verified by an experienced neuroradiologist (B.B.) in a consensus reading with the first reader for a final decision.

2.4.1. Lesion Assessment

All inflammatory lesions recorded were documented and listed. Identifiers were assigned, using all sequence contrasts available, particularly axial reconstructions including 3D multiplanar reconstructions (MPRs) of FLAIR₃D, DIR, and T1-MPRAGE, plus an axial T2-TSE sequence contrast. Utilization of all these contrasts was referred to as gold standard (GS). Accordingly, the total amount of lesion counts was referred to as true positives using GS (TPGs). To each TPGs lesion, the following attributes were assigned (see Figure 2): 1) clearly detectable as a lesion using only the axial reconstruction of FLAIR₃D (FLAIR₃Da), i.e., true positive in FLAIR₃Da (TP₃Da), or not clearly detectable as a lesion using only FLAIR₃Da, i.e., false negative in FLAIR₃Da (FN₃Da); 2) clearly detectable as a lesion using only the FLAIRUF images (TPUF), or not clearly detectable as a lesion using only the FLAIRUF images (TPUF), or not clearly detectable as a lesion using only the FLAIRUF images (FNUF); 3) lesion size, i.e., lengthwise axial diameter (mm, to the nearest tenth); 4) lesion size category, i.e., lengthwise axial diameter (large [≥ 3 mm] or small [< 3 mm]); 5) location, i.e., brain region (frontal, parietal, temporal, occipital, central [insular lobe, corpus callosum, basal nuclei, diencephalon], or infratentorial [brainstem, cerebellum]).

The following attributes were assigned to only a particular subset of the TPGs lesions (see also Figure 2): 1) lesion width (wide [\geq 2 mm] or narrow [< 2 mm]; axial) and lesion location, according to Barkhof et al. and the McDonald criteria [6–9,13,65] (characteristic [periventricular, juxta-/cortical, infratentorial] or not characteristic) were both assigned to large (\geq 3 mm) TPGs lesions only; 2) lesion detectability in FLAIRTSE (TPTSE or FNTSE) was assigned to the subset of TPGS recorded with FLAIRTSE (tseTPGS); 3) lesion conspicuity in FLAIRUF compared with FLAIR3Da counterpart, using an ordinal five-point Likert scale (1 = better/larger in the FLAIRUF images; 2 = equal; 3 = better in the FLAIR3Da images, but classified as a lesion using only the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not at all visible in the FLAIRUF images), was only assigned to the TP3Da lesions; 4) presumed causes for not being detected in FLAIRUF were only assigned to the FNUF lesions; 5) presumed causes for not being detected in FLAIR3Da were only assigned to the FNUF lesions; 6) presumed causes for not being detected in FLAIR3Da were only assigned to the FNUF lesions; 6) presumed causes for not being

False positive (FP) lesions were recorded and listed separately for FLAIR_{UF} (FP_{UF}), FLAIR_{3Da} (FP_{3Da}), and FLAIR_{TSE} (FP_{TSE}). To each FP lesion, the following attributes were assigned (see Figure 3): 1) size category, i.e., lengthwise axial diameter (large [≥ 3 mm] or small [< 3 mm]); 2) presumed causes for being mistaken for a lesion.




Figure 2. Classification of TPGs lesions. Note. TPGs lesions = total number of true positive lesions detected using all contrasts available (gold standard); FLAIR3Da = axial reconstruction of FLAIR3D; FLAIRUF = ultrafast axial FLAIR; tseTPGs = subset of TPGs recorded with FLAIRTSE; FLAIRTSE = axial standard TSE-FLAIR; GS = utilization of all contrasts available, particularly T2-FLAIR, T1, and T2; TP = true-positives; FN = false-negatives; 1 = better/larger in the FLAIRUF images compared to FLAIR3Da; 2 = equal compared to FLAIR3Da; 3 = better in the FLAIR3Da images, but classified as a lesion using only

the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not at all visible in the FLAIRUF images; PV = periventricular; (J-)C = (juxta-)cortical; I = infratentorial (brainstem, cerebellum); F = frontal; P = parietal; T = temporal; O = occipital; C = central (insular lobe, corpus callosum, basal nuclei, diencephalon).




Figure 3. Classification of FP lesions. Note. FP = false positive; further abbreviations as in Figure 2.

2.4.2. Image Quality Assessment

For the purpose of general image quality assessment, three parameters were employed: signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and artifacts. FLAIR_{UF}, FLAIR_{3Da} and FLAIR_{TSE} slice series were each rated for SNR and CNR on an ordinal five-point Likert scale (1 = very good; 2 = good; 3 = acceptable; 4 = mediocre but diagnostic; 5 = poor and non-diagnostic). Besides, all artifacts in the FLAIR_{UF}, FLAIR_{3Da}, and FLAIR_{TSE} images were assessed based on quantity and quality. To this end, FLAIR_{UF}, FLAIR_{3Da}, and FLAIR_{TSE} sequences were classified as to their limitations of diagnostic information in the respective artifact region, using an ordinal five-point Likert scale (0 = No artifact; 1 = Artifact exists, but diagnostic information is not limited; 2 = Artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = Artifact exists, and diagnostic information is limited in the artifact region; 4 = Artifact exists, and diagnostic information is severely limited in the artifact region).

To assess location-dependent SNR and CNR within the FLAIR_{UF} images, the following attributes were assigned to each TP_{GS} lesion (see previous section): 1) SNR in the vicinity of the lesion (standard or substandard; with reference to the average SNR in FLAIR_{UF}); 2) CNR in the vicinity of the lesion (standard or substandard; with reference to the average CNR in FLAIR_{UF}).

2.5. Statistical Analysis

Statistical analyses were performed post hoc using SPSS (IBM SPSS Statistics Version 29.0.0.0, IBM Corp., Armonk, NY, USA) and Excel (Microsoft Excel for Microsoft 365 MSO Version 2305, Microsoft Corp., Redmond, WA, USA).

In order to compare lesion detection in FLAIRUF with lesion detection in FLAIR3Da, contingency tables were created, correlating TP and FN lesion counts. Also, the counts and presumed causes of FN and FP lesions were contrasted. The sensitivity values (TP/[TP+FN]) and positive predictive values (PPVs; TP/[TP+FP]) as to lesion detection were specified including their 95% Clopper-Pearson confidence intervals (CIs), and FN lesion counts were compared using McNemar's test (Excel). The same analyses were performed to compare the lesion detection in FLAIRUF with the lesion detection in FLAIRTSE. To ascertain factors that affect the lesion conspicuity within the FLAIRUF images, conspicuity ratings were compared, grouped by lesion size and location, using the Wilcoxon ranksum test and the Kruskal-Wallis test (SPSS). With the aim to investigate whether conspicuity ratings might possibly have been biased by lesion size variations among the location groups, lengthwise diameters of the TP3Da lesions were reported for each location (mean/95% CI, standard deviation [SD], median) and compared using the Kruskal-Wallis test (SPSS). Moreover, large TP3Da lesions (\geq 3 mm) for each brain region were divided into wide (\geq 2 mm) and narrow (< 2 mm) lesions and were further differentiated by conspicuity ratings.

For the purpose of contrasting the ordinal SNR, CNR and artifact ratings in the FLAIR_{UF} and FLAIR_{3Da} image series, results were reported as median plus interquartile range (IQR) as well as mean ± SD; a Wilcoxon signed-rank test was also performed (SPSS). Similarly, results were reported for comparing FLAIR_{UF} with FLAIR_{TSE} image series. To ascertain positional factors that affect the SNR and CNR within the FLAIR_{UF} images, the dichotomous SNR and CNR ratings were grouped by location; the proportions of the substandard ratings were determined for each group including 95% Clopper-Pearson CIs. Groups were compared using the chi-squared test (Excel).

In [66] Bender et al. stated that multiple testing corrections are not necessarily required for exploratory trials generating (diverse) hypotheses. Accordingly, adjustment for multiple comparisons was waived for this study. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Image Acquisitions and Lesions

Image data includes seventeen FLAIRuf sequences, seventeen corresponding FLAIR3D sequences, and three additional FLAIRTSE sequences, which could all be acquired from seventeen MRI examinations in sixteen different RRMS patients (twelve males, five females). The patients' mean age was 29 years, with ages ranging from 21 to 60 years (see Table 1). Lesion counts are listed in detail in Figures 5 and 9 and visualized schematically in Figures 4 and 8. In total, we counted 568 true positive lesions using the gold standard (TPGs), i.e., actual inflammatory brain lesions detected using all contrasts available as described in Section 2.4.1. Of the 568 existing lesions, 288 (50.7%) were categorized as 'large lesions' (≥ 3 mm total), and 280 (49.3%) were classed as 'small lesions' (< 3 mm). Of the 288 large lesions, 171 (59.4%) were named as 'wide lesions' (width ≥ 2 mm), and 117 (40.6%) were labeled 'narrow lesions' (width < 2 mm). Taking account of all 568 lesions, there were 542 (95.4%) of them that could be detected using only the FLAIR_{3Da} images, hence referred to as TP_{3Da} lesions. Of the 542 TP_{3Da} lesions, 274 (50.6%) were large and 268 (49.4%) were small. The count of wide large TP_{3Da} lesions was 163 (59.5%), and the count of narrow large TP_{3Da} lesions was 111 (40.5%). The mean count of TPcs lesions and standard deviation per patient was 33 ± 21, with counts ranging from 1 to 87. Taking account of all 288 large TPcs lesions, there were 191 (66.3%) lesions grouped as 'characteristic MS lesions', which were subdivided into three groups: 109 (57.1%) periventricular lesions, 44 (23.0%) infratentorial lesions, and 38 (19.9%) (juxta-)cortical lesions. All lesion counts, including TPuF lesions and all corresponding FN lesion counts, correlated with each other, are considered in the following section.

3.2. Lesion Detection

3.2.1. FLAIR_{UF} Compared with FLAIR_{3Da}

Correlations between TPuf, FNuf, TP $_{3Da}$, FN $_{3Da}$, and TPGs lesions are schematically demonstrated in Figure 4. Lesion counts are specified in Figure 5, classified by size (large, small, wide, narrow). All counts of total TP and total FN lesions, as well as FP lesions, in both the FLAIRuf images and FLAIR $_{3Da}$ images, were analyzed, compared, and grouped by size.




Figure 4. Correlations between TPuF, FNuF, TP3Da, FN3Da, and TPGs lesion counts. Schematic illustration (a) and contingency table (b). Note. TPGs = number of true positive lesions detected using all contrasts available (gold standard); TPuF = true positive lesions detected in the FLAIRuF images; FNUF = false negative lesions using the FLAIRuF images; TP3Da = true positive lesions detected in the FLAIR3Da images; FN3Da = false negative lesions using the FLAIR3Da images.




Figure 5. Contingency tables correlating TP_{UF}, FN_{UF}, TP_{3Da}, FN_{3Da}, and TP_{GS} lesion counts, grouped by size, according to Figure 4. Note. Abbreviations as in Figure 4. ¹ 191 of them were 'characteristic MS lesions', including 109 periventricular lesions, 44 infratentorial lesions, and 38 (juxta-)cortical lesions.

The sensitivity and PPV in terms of lesion detection using FLAIR_{UF} compared with FLAIR_{3Da} are analyzed in Table 3 and visualized in Figure 6. For wide lesions, no statistically significant differences could be found in either sensitivity (p = 0.50) or PPV (overlap between confidence intervals). Neither was there a significant difference in PPV for narrow lesions (overlap between confidence intervals). Nevertheless, the sensitivity was significantly inferior in the FLAIR_{UF} images for narrow large lesions (p < 0.001). For small lesions, the PPV was reduced in the FLAIR_{UF} images compared with the FLAIR_{3Da} images (no overlap between confidence intervals), and the sensitivity was considerably lower in the FLAIR_{UF} images compared with the FLAIR_{3Da} images (p < 0.001).

Table 3. Lesion detection in FLAIRUF images and FLAIR3Da images.

		То	tal			Sensitiv	vity	PPV
Lesion size	S	TP	FN	TPGS	FP	95% CI [LL, UL]	р	95% CI [LL, UL]
		п	п	п	п	%		%
Large	UF	251	37	200	11	87.2 [82.7, 90.8]	< 0.001	95.8 [92.6, 97.9]
(≥ 3 mm)	3Da	274	14	288	11	95.1 [92.0, 97.3]	< 0.001	96.1 [93.2, 98.1]
Wide	UF	160	11	171	6	93.6 [88.8, 96.7]	0.50	96.4 [92.3, 98.7]
$(x \ge 2 \text{ mm})$	3Da	163	8	1/1	8	95.3 [91.0, 98.0]	0.50	95.3 [91.0, 98.0]
Narrow	UF	91	26	117	5	77.8 [69.2, 84.9]	< 0.001	94.8 [88.3, 98.3]
$(\times < 2 \text{ mm})$	3Da	111	6	11/	3	94.9 [89.2, 98.1]	< 0.001	97.4 [92.5, 99.5]
Small	UF	148	132	200	33	52.9 [46.8, 58.8]	< 0.001	81.8 [75.4, 87.1]
(< 3 mm)	3Da	268	12	280	15	95.7 [92.6, 97.8]	< 0.001	94.7 [91.4, 97.0]

Note. S = sequence; UF = FLAIR_{UF}; 3Da = FLAIR_{3Da}; PPV = positive predictive value; CI = confidence interval (Clopper-Pearson); LL = lower limit; UL = upper limit; further abbreviations as in Figures 2, 3, and 4. To compare sensitivity results (or, more precisely, to compare the FN_{UF} & TP_{3Da} lesion counts with the FN_{3Da} & TP_{UF} lesion counts) McNemar's test was performed, based on paired data shown in Figure 5. To compare PPV results, no statistical test was performed, since data were neither completely paired nor complete independent samples.




Figure 6. Sensitivity and PPV in terms of lesion detection, using FLAIRuF images (gray) and FLAIRaDa images (white). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs. (a) For wide lesions, no significant difference in sensitivity could be found. For the groups that comprise smaller lesions, however, the sensitivity was significantly inferior using the FLAIRuF images, decreasing more and more as a function of lesion diameter. (b) No significant differences in PPV were found for any of the large lesion groups (large, wide, and narrow). For small lesions, the PPV in the FLAIRuF images was moderately lower compared to the FLAIRaDa group (no overlap between confidence intervals). Note. Abbreviations as in Table 3. * p < 0.05.

Presumed causes of FN lesions in both image variants are quantified in Table 4 (large) and Table 5 (small). Presumed causes for lesions not being detected using FLAIRuf were: 1) lesions were not visible owing to a combination of insufficient levels of spatial resolution, CNR, and SNR; 2) lesions were mistaken for cortex or other physiological structures owing to a combination of insufficient levels of spatial resolution, CNR, and SNR; 3) lesions were concealed by distortion artifacts. Similarly, presumed causes for lesions not being detected using FLAIR3Da were: 1) lesions were mistaken for or masked by (mostly infratentorial) pulsation artifacts; 2) lesions were mistaken for cortex or other physiological structures; 3) lesions were not visible at all, likely due to low resolution-related lesion contrast. Image examples of FNuf lesions and corresponding TP3Da lesions are given in Figures 7 and 13c. Images of a FN3Da lesion including the corresponding TPuf lesion are shown in Figure 15b.

Frequent causes of FP lesions were in each case: partially imaged cortex or infratentorial pulsation artifacts appearing like lesions. While the former could be observed more frequently than the latter in the FLAIR_{UF} images, they occurred at a similar rate in the FLAIR_{3Da} images. Comprehensive results are reported in Table 6. Image examples of FP_{UF} and FP_{3Da} lesions are given in Figures 15 and 16e.

Table 4. Presumed causes of FN large lesions (≥ 3 mm total) in FLAIR_{UF} and FLAIR_{3Da} images.

		F	LAIRUF			FLAIR3Da		
Presumed type of cause		FN _{UF} total	FNuf & TP3Da		Tuf &	FN3Da & TPuf	FN3Da total	
		n	п	п	п	п	n	
Not detectable	SR/CNR/SNR	28	22	6	0	1	1	
Mistaken for natural structure ¹	2	7	4	3	3	0	3	
Mistaken for/masked by pu	0	0	0	7 ³	3 ³	10 ³		
Masked by distortion artifact		2	1	1	0	0	0	
Total		37	27		10	4	14	

Note. SR = spatial resolution, esp. slice thickness; CNR = contrast-to-noise ratio; SNR = signal-to-noise ratio; further abbreviations as in Figures 2 and 4. ¹ Cortex, in particular. ² Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases. ³ All lesions were located in an infratentorial position.

Table 5. Presumed causes of FN small lesions (< 3 mm) in FLAIRuf and FLAIR3Da images.

		F	LAIRUF			FLAIR3Da		
Presumed type of cause			FNuf & TP3Da		Juf &	FN3Da & TPuf	FN3Da total	
		n	n	n	n	п	n	
Not detectable	SR/CNR/SNR	110	105	5	0	3	3	
Mistaken for natural structure ¹	2	21	19	2	3	1	4	
Mistaken for/masked by pulsation artifact			0	0	5 ³	0	5 ³	
Masked by distortion artifact			0	1	0	0	0	
Total	_	132	124	•	8	4	12	

Note. Abbreviations as in Table 4. ¹ Cortex, in particular. ² Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases. ³ Three were located in an infratentorial position; the rest were located in a supratentorial position.




Figure 7. FNuf lesions (top row) contrasted with their TP_{3Da} counterparts (arrow, bottom row). The images also show several other lesions. (a) Lesion in the splenium of the corpus callosum (approx. 3 mm × 2 mm). Causes for it not being detected may be image noise and slice thickness/slice gaps. (b) Left frontal lesion (approx. 3 mm × 1 mm). Causes may be associated with slice thickness/contrast as well as image noise. (c) Thin right frontal lesion (approx. 7 mm × 1 mm). It was mistaken for cortex in the FLAIRuf image. (d) Left temporopolar lesion (approx. 3 mm × 2 mm). It was not recognized as such in the FLAIRuf image owing to commonly occurring distortions within this region.

Note. Corresponding slices could not be positioned exactly identically for two reasons: Different slice thicknesses including slice gaps (c) and non-parallel slice inclinations (d).

Table 6. Presumed causes of FP lesions in FLAIR_{UF} and FLAIR_{3Da} images.

		I	FLAIRUF		FLAIR3Da			
		FPuf	FPUF		FP _{3Da}	$FP_{^{3Da}}$		
Dragum ad gaugal phonomonon		Large	Small	$\mathbf{FP}_{\mathbf{UF}}$	Large	Small	$\mathbf{FP}_{^{3\mathrm{Da}}}$	
Presumed causal phenomenon		(≥ 3	(< 3	total	(≥3	(<3	total	
		mm)	mm)		mm)	mm)		
		N	п	n	п	п	n	
Partially imaged natural		9	24	33	6	7	13	
structure ¹	SR	9	24	33	O	/	13	
Partially imaged nearby large	2	0	2	2	0	1	1	
lesion		U	2	2	U	1	1	
Pulsation artifact		2 3	7 ³	9 ³	5 4	7 5	12 ⁵	
Total	•	11	33	44	11	15	26	

Note. SR = spatial resolution, esp. slice thickness; FP_{UF} = false positive lesions using the FLAIR_{UF} images; FP_{3Da} = false positive lesions using the FLAIR_{3Da} images. ¹ Cortex, in particular. ² CNR and SNR also partly involved. ³ One was located in a supratentorial position; the rest were located in an infratentorial position. ⁴ All lesions were located in an infratentorial position. ⁵ Three were located in a supratentorial position; the rest were located in an infratentorial position.

3.2.2. FLAIRUF Compared with FLAIRTSE

To compare FLAIRUF with FLAIRTSE images, all FLAIRTSE data available were utilized and matched with their FLAIRUF counterparts. TPTSE and FNTSE lesion counts added up to the corresponding subset of TPGS lesion counts (tseTPGS). Again, tseTPGS could be divided into

corresponding subsets of TPuf and FNuf lesions each (tseTPuf and tseFNuf). Correlations between tseTPuf, tseFNuf, TPtse, FNtse, and tseTPcs lesions are schematically demonstrated in Figure 8. Lesion counts are given in Figure 9, classified by size (large, small, wide, narrow). Image examples of TP lesions in FLAIRuf, FLAIRtse, and FLAIR3Da are shown side by side in Figure 10. FPtse lesion counts along with corresponding tseFPuf counts can be found in Table 10.




Figure 8. Correlations between tseTPuF, tseFNuF, TPTsE, FNTSE, and tseTPcs lesion counts. Schematic illustration (a) and contingency table (b). Note. TPcs = number of true positive lesions detected using all contrasts available (gold standard); tseTPcs = subset of TPcs recorded with FLAIRTSE; tseTPuF = corresponding subset of TPuF recorded with FLAIRTSE; tseFNuF = corresponding subset of FNuF recorded with FLAIRTSE; TPTSE = true positive lesions detected in the FLAIRTSE images; FNTSE = false negative lesions using the FLAIRTSE images; further abbreviations as in Figure 4.




Figure 9. Contingency tables including a subset of those TPGs lesions covered by the FLAIRTSE sequence (tseTPGs). tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesion counts are correlated, grouped by size, according to Figure 8. Note. Abbreviations as in Figure 8. ¹ One was FN using FLAIR3Da; the rest were TP in FLAIR3Da. ² Two were FN using FLAIR3Da; the rest were TP in FLAIR3Da. ³ Three were FN using FLAIR3Da; the rest were TP in FLAIR3Da. ⁴ Four were FN using FLAIR3Da; the rest were TP in FLAIR3Da. Lesion counts without superscripts were all TP in FLAIR3Da.




Figure 10. An MS patient received an MRI scan including three T2w FLAIR sequences: FLAIR_{UF} (**a**), FLAIR_{TSE} (**b**) and FLAIR_{3D} (**c**). Five lesions can be seen in each picture, situated in the frontoparietal region.

The proportions of total TP lesions in both the FLAIR_{TSE} and the corresponding FLAIR_{UF} images are further analyzed in Table 7 and visualized in Figure 11, graded as to size. The sensitivity in terms of lesion detection did not differ significantly between the image variants in large (p = 0.68), wide (p > 0.99), or narrow (p > 0.99) lesion groups. For detecting small lesions, the sensitivity was lower using the FLAIR_{UF} images, however, the difference could not be confirmed statistically (p = 0.08).

	Table 7. Lesion	detectability in 1	FLAIRTSE images	and FLAIRUEC	ounterparts.
--	-----------------	--------------------	-----------------	--------------	--------------

		To	otal		Sensitivity		
Lesion size	S	tseTP	tseFN	tseTPcs	95% CI [LL, UL]	p	
		n	п	п	%		
Large	UF	48	5	53	90.6 [79.3, 96.9]	0.69	
(≥ 3 mm)	TSE	48	5	33	90.6 [79.3, 96.9]	0.68	
Wide	UF	33	2	25	94.3 [80.8, 99.3]	> 0.00	
$(\times \ge 2 \text{ mm})$	TSE	34	1	35	97.1 [85.1, 99.9]	> 0.99	
Narrow	UF	15	3	10	83.3 [58.6, 96.4]	> 0.00	
$(\times < 2 \text{ mm})$	TSE	14	4	18	77.8 [52.4, 93.6]	> 0.99	
Small	UF	19	15	24	55.9 [37.9, 72.8]	0.00	
(< 3 mm)	TSE	27	7	34	79.4 [62.1, 91.3]	0.08	

Note. TSE = FLAIR_{TSE}; further abbreviations as in Table 3 and Figure 8. To compare sensitivity results, McNemar's test was performed, based on paired data shown in Figure 9. Unlike in the previous section, the corresponding FP values (see Table 10) were insufficient to ensure reliable PPV analysis results; hence, it was omitted here.




Figure 11. Sensitivity in terms of lesion detection, using FLAIR_{TSE} images (white) and corresponding FLAIR_{UF} images (gray). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs. No significant differences in sensitivity could be detected for any of the lesion groups (p > 0.05). For small lesions, however, the data suggests a lower sensitivity using the FLAIR_{UF} images compared to the FLAIR_{TSE} images. Results imply that there is a correlation between lesion detectability and size in both cases, though. Note. Abbreviations as in Table 7.

Presumed causes of FN lesions in both image variants are quantified in Table 8 (large) and Table 9 (small). Causes for lesions not being detected appear to be relatively similar in the FLAIR_{UF} and FLAIR_{TSE} images: 1) lesions were not visible owing to resolution-associated lesion contrast or did not sufficiently stand out from image noise; 2) lesions were mistaken for cortex or other physiological structures. Table 10 summarizes the presumed causes of FP lesions.

Table 8. Presumed causes of FN large lesions (≥ 3 mm total) in FLAIR_{TSE} and corresponding FLAIR_{TSE} images.

			FLAIRuf		FLAIRTSE			
		tseFN∪ tseF		tseFNur &		FNtse &	FNTSE	
Presumed type of cause		F	&	FN _{TSE}		tseTPu	total	
	_	total	TPTSE	FIN	TISE	tserrur	total	
		n	п	n	n	n	n	
Not detectable	SR/CNR/SNR	3	3	0	0	3	3	
Mistaken for natural	SK/CINK/SINK	2	0	2	2	0	2	
structure ¹	2	2	U	2	2	U	2	
Total		5	3	2	2	3	5	

Note. Abbreviations as in Table 4 and Figure 8. ¹ Cortex, in particular. ² Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases.

Table 9. Presumed causes of FN small lesions (< 3 mm) in FLAIRTSE and corresponding FLAIRTSE images.

			FLAIRUF			FLAIRTSE		
		tseFN _U	tseFNuf	tooEN	.T θ_	FNtse &	FNTSE	
Presumed type of cause		F	tseFNuf & FNtse			tseTPuf	total	
	_	total	TPTSE	FIN	TISE	tserrur	totai	
		n	n	n	n	n	n	
Not detectable	CD/CNID/CNID	13	10	3	3	3	6	
Mistaken for natural	SR/CNR/SNR	2	2	0	0	1	1	
structure ¹	2	2	2	0	0	1	1	
Total		15	12	3	3	4	7	

Note. Abbreviations as in Table 4 and Figure 8. ¹ Cortex, in particular. ² Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases.

Table 10. Presumed causes of FP lesions in FLAIR_{UF} and FLAIR_{3Da} images.

			FLAIRUF	_	FLAIRTSE			
		tseFPuf	tseFPuf		FPTSE	FPTSE		
Drocum ad causal phonomonon		Large	Small	tseFP UF	Large	Small	FP _{TSE}	
Presumed causal phenomenon		(≥3	(< 3	total	(≥3	(< 3	total	
	_	mm)	mm)		mm)	mm)		
		n	n	n	n	n	n	
Partially imaged natural		1	1	2	1	3	4	
structure ¹	SR	1	1	2	1	3	4	
Partially imaged nearby large 2	2	0	1	1	0	1	1	
lesion		U	1	1	U	1	1	
Total		1	2	3	1	4	5	

Note. SR = spatial resolution, esp. slice thickness; $FP_{TSE} = false$ positive lesions using the FLAIR_{TSE} images; $tseFP_{UF} = corresponding subset of FP_{UF} recorded with FLAIR_{TSE}. ¹ Cortex, in particular. ² CNR and SNR also partly involved.$

3.2.3. Dependence on Size and Location within FLAIRuf

Unlike in Sections 3.2.1 and 3.2.2, results of ordinal lesion conspicuity ratings of the FLAIRuf images, based on the FLAIRaba images, are presented in this section. Comprehensive conspicuity ratings are given in Table 11 and visualized in Figure 12, grouped by lesion size and brain regions. As alluded to in Section 3.2.1, there could be demonstrated a statistically significant difference in terms of lesion conspicuity between large and small FLAIRuf lesions (p < 0.001). Testing for conspicuity differences between frontal, parietal, temporal, occipital, central, and infratentorial lesions was significant within the large lesion group (p = 0.002), but not among small lesions (p = 0.15). Further analysis of large lesions revealed that the differences could be attributed to occipital and central lesions. Conspicuity of large lesions among all the other regions did not differ significantly (p = 0.42). Occipital large lesions proved to be more conspicuous (p = 0.002) and central large lesions proved to be less conspicuous (p = 0.01) compared to all the other large lesions (frontal, parietal, temporal, and infratentorial).

Nevertheless, the results are only valid if they are not biased by other parameters, particularly lesion size variations among the brain regions. Therefore, the average lengthwise lesion diameters are compared in Table 12. The results show that there is no significant or relevant deviation of any group, either for large lesions (p = 0.26) or small lesions (p = 0.06). Moreover, Table 13 demonstrates the distribution of large lesions between wide and narrow lesions, clustered by location. Also, each group is differentiated by conspicuity ratings. In comparison to all the other locations, there were two brain regions where there were relatively more wide lesions than narrow lesions: occipital and infratentorial. The conspicuity ratings of wide infratentorial lesions appear to be better than the

conspicuity ratings of narrow infratentorial lesions; however, that did not hold true for occipital lesions (good ratings without exception).

Table 11. Conspicuity ratings of lesions in the FLAIRuF images, categorized by size and location.

			Con	spicı	ıity			
Size	Location	1	2	3	4	5	TP _{3Da}	р
		n	п	п	п	п	п	
Large (≥ 3 mm total)	All	37	180	30	13	14	274	< 0.001 ³
Small (< 3 mm)	All	12	94	38	44	80	268	V 0.001
	Frontal	7	55	4	4	3	73	
	Parietal	5	40	6	4	3	58	
Large	Temporal	12	48	7	2	3	72	0.002 4
(≥3 mm total)	Occipital	6	9	0	0	0	15	0.002
	Central ¹	3	7	8	3	1	22	
	Infratentorial ²	4	21	5	0	4	34	
	Frontal	7	46	16	16	25	110	
	Parietal	2	20	10	6	22	60	
Small	Temporal	3	16	7	14	20	60	0.15 4
(< 3 mm)	Occipital	0	0	1	1	1	3	0.15 4
	Central ¹	0	11	4	5	11	31	
	Infratentorial ²	0	1	0	2	1	4	
	Frontal	7	55	4	4	3	73	
Large	Parietal	5	40	6	4	3	58	0.42 4
(≥3 mm total)	Temporal	12	48	7	2	3	72	0.42
	Infratentorial ²	4	21	5	0	4	34	
	Occipital	6	9	0	0	0	15	
								0.002^{3}
Small (≥3 mm total)	Frontal & Parietal & Temporal & Infratentorial ²	28	164	22	10	13	237	
	Central ¹	3	7	8	3	1	22	0.01 ³

Note. TP_{3Da} = true positive lesion counts using FLAIR_{3Da}. The counts of lesions are given. The conspicuity was rated on an ordinal five-point Likert scale, based on the FLAIR_{3Da} images: 1 = better/larger in the FLAIR_{UF} images; 2 = equal; 3 = better in the FLAIR_{3Da} images but classified as a lesion using only the FLAIR_{3Da} images; 4 = better in the FLAIR_{3Da} images and classified as no lesion using only the FLAIR_{UF} images; 5 = FLAIR_{3Da} lesion that is not visible at all in the FLAIR_{UF} images. ¹ Insular lobe, corpus callosum, basal nuclei, and diencephalon. ² Brainstem and cerebellum. ³ Wilcoxon rank-sum test. ⁴ Kruskal-Wallis test.




Figure 12. Conspicuity ratings of lesions in the FLAIRuF images, categorized by size and location. Lesion conspicuity was significantly superior for large lesions compared to small lesions. Unless for small lesions, there was a significant difference among some brain regions for large lesions. This could be attributed to occipital lesions (superior) and central lesions (inferior).

Note. Black = 1; dark gray = 2; gray = 3; light gray = 4; white = 5. Abbreviations and brain regions as in Table 11. * p < 0.05.

Table 12. Average lesion diameters (lengthwise), grouped by size category and location.

		Large (≥3	mm to	otal)			Small (<	< 3 mm	ı)		
		M & 95%					M & 95%				
Location	$\mathrm{TP}_{^{3\mathrm{Da}}}$	CI	SD	Mdn	n	$\mathrm{TP}_{^{3\mathrm{Da}}}$	CI	SD	Mdn	n	
		[LL, UL]			p		[LL, UL]			p	
	п	mm	mm	mm		n	mm	mm	mm		
Frontal	73	5.1 [4.6, 5.6]	1.9	4.6		110	2.1 [2.0, 2.2]	0.5	2.3		
Parietal	58	5.8 [5.0, 6.7]	3.2	4.6		60	2.1 [1.9, 2.2]	0.6	2.1		
Temporal	72	5.3 [4.7, 5.9]	2.5	4.6	0.26	60	2.0 [1.8, 2.1]	0.6	2.1	0.06	
Occipital	15	5.6 [4.6, 6.6]	1.8	5.4	0.26	3	2.8 [2.6, 2.9]	0.1	2.8	0.06	
Central	22	5.5 [3.8, 7.2]	3.8	4.5		31	2.2 [2.1, 2.4]	0.5	2.4		
Infratentorial	34	6.5 [5.4, 7.5]	3.0	5.2		4	2.3 [1.9, 2.8]	0.3	2.4		
Total	274	5.5 [5.2, 5.9]	2.7	4.7		268	2.1 [2.0, 2.2]	0.6	2.2		

Note. M = mean; CI = confidence interval; LL = lower limit; UL =upper limit; SD = standard deviation; Mdn = median; further abbreviations and brain regions as in Table 11. Since the assumptions of normal distribution of the data were not met, a Kruskal-Wallis test was performed.

Table 13. Conspicuity ratings of large lesions (≥ 3 mm), grouped by width category and location.

		Wide (≥ 3 mm × ≥ 2 mm)					Narrow (≥ 3 mm × < 2 mm)						Large (≥ 3 mm total)	
Location	-	Conspicuity				Tr . 1	Conspicuity					T (1	TD	
	1	2	3	4	5	- Total	1 2 3 4 5 Total		Total	$ ext{TP}_{3Da}$				
	п	п	n	п	п	п	n	N	п	п	п	n	n	
Frontal	7	35	0	0	1	43	0	20	4	4	2	30	73	
Parietal	2	28	2	1	0	33	3	12	4	3	3	25	58	
Temporal	5	30	4	1	0	40	7	18	3	1	3	32	72	
Occipital	4	8	0	0	0	12	2	1	0	0	0	3	15	
Central	0	4	5	1	0	10	3	3	3	2	1	12	22	
Infratentorial	3	17	3	0	2	25	1	4	2	0	2	9	34	
Total	21	122	14	3	3	163	16	58	16	10	11	111	274	

Note. The counts of lesions are given. Abbreviations and brain regions as in Table 11.

3.3. *Image quality*

3.3.1. FLAIRUF Compared with FLAIR3Da

SNR and CNR in the FLAIR $_{^{3}Da}$ images were rated significantly inferior compared to the FLAIR $_{^{3}Da}$ images (p < 0.001 each). Rating results are given in Table 14. They represent overall judgments of the slice series. In fact, there were inequal SNR and CNR levels among the slices and there was also a positional dependence within one image slice. This is further examined in Section 3.3.3. For image examples, see Figure 13.

Table 14. SNR and CNR in FLAIRUF and FLAIR3Da images.

	I	FLAIRUF		F			
Parameter	Mdn (IQR)	M ± SD	L/ H	Mdn (IQR)	M ± SD	L/ H	p
SNR	3 (3-3)	3.00 ± 0.00	3/3	1 (1-1)	1.18 ± 0.39	1/2	< 0.001
CNR	3 (2-3)	2.53 ± 0.51	2/3	1 (1-1)	1.18 ± 0.39	1/2	< 0.001

Note. N = 17. SNR = signal-to-noise ratio; CNR = contrast-to-noise ratio; Mdn = median; IQR = interquartile range; <math>M = mean; SD = standard deviation; L = lowest value; H = highest value. Both parameters were rated on an ordinal five-point Likert scale: 1 = very good; 2 = good; 3 = acceptable; 4 = mediocre/diagnostic; 5 = poor/non-diagnostic. The p-values were calculated using the Wilcoxon signed-rank test.




Figure 13. SNR and CNR in FLAIR_{UF} images (top) and FLAIR_{3Da} images (bottom). (a) Inflammatory lesions. Continuous arrow: Large lesion in the right mesencephalon (approx. 8 mm × 6 mm). The SNR appeared reduced in the center of the FLAIR_{UF} image, thus decreasing the lesion conspicuity. Dotted arrows: Temporal lesions (right: approx. 5 mm × 4 mm; left: approx. 4mm × 3 mm). The SNR appeared significantly improved in posterior brain regions in the FLAIR_{UF} images, thus equaling lesion conspicuity between the image variants. Note that in FLAIR_{3Da}, the left lesion was better visible in the adjacent image slice (not depicted). Arrowhead: Partially imaged, right temporal lesion (approx. 3 mm × 1 mm in the slice image depicted). Comparison of adjacent slice images showed equal lesion

conspicuity. (b) Arrow: Left frontal lesion (approx. 2 mm × 1 mm). Excellent lesion conspicuity in the FLAIRuf image due to very good SNR and CNR. (c) Infratentorial lesions. Continuous arrow: Large lesion (approx. 9 mm × 6 mm) that was not visible in the FLAIRuf image owing to low SNR and CNR. Dotted arrow: Large lesion (approx. 8 mm × 6 mm) that was less visible in the FLAIRuf image due to reduced SNR and CNR. Arrowhead: Large lesion (approx. 3 mm × 2 mm) that was better visible in the FLAIRuf image. Note that the SNR improves towards the outer regions of the FLAIRuf image.

Table 15 lists all artifacts that could be identified in each sequence variant and shows detailed results. Image series were rated positive for artifacts in case the artifact could be detected in at least one image slice. First of all, spatial distortions occurred in each of the FLAIRuf sequences, and did not appear in any of the FLAIR_{3D} sequences, representing the main difference. Regions of distortions were as follows: frontal, frontobasal, temporopolar, and infratentorial. As an example, see the images of spatial distortions (Figure 14) as well as the image of a temporopolar distortion-related FN lesion in Figure 7d. Furthermore, we observed infratentorial pulsatile flow artifacts in all sequences, in both the FLAIR_{UF} images and the FLAIR_{3Da} images. Pulsation artifacts (infratentorial and supratentorial) in the FLAIRuf images typically appeared as hyperintense or hypointense dots, spots, or streaks. Pulsation artifacts in the FLAIR_{3Da} images, however, typically appeared as grainy, hyperintense artifact bands positioned at the level of the pons. Limitation of diagnostic information was assumed if there was a tendency or possibility of artifacts mimicking or masking lesions. The former mainly applied to the FLAIR UF images, and the latter mainly pertained to the FLAIR Images. Infratentorial pulsation artifacts and related limitations of diagnostic information are demonstrated in Figure 15. Aside from that, we found other infrequent minor artifacts almost not affecting diagnostic information and occurring only in the FLAIRUF images: Supratentorial pulsation artifacts, frontal chemical shift artifacts due to incomplete fat suppression, central residual aliasing, and spike artifacts. Plus, there were some motion artifacts in one FLAIR₃Da image series that could not be seen in the corresponding FLAIRuf images. Image examples of those minor artifacts are presented in Figure 16.




Figure 14. Spatial distortion artifacts in the FLAIRUF images. (a) Frontal distortion artifact limiting the diagnostic information in that region. (b) Frontabasal distortion artifacts resulting in limited diagnostic information from that region. (c) Temporopolar distortion artifacts limiting the diagnostic information in the vicinity. In contrast, the cerebellar and pontine distortion artifacts do not limit diagnostic information.

Table 15. Artifacts in the FLAIRUF and FLAIR3Da images.

	F	LAIRuf		F	FLAIR3Da				
Artifacts	Mdn	M ± SD	L/	Mdn	M ± SD	L/	p		
-	(IQR)	171 2 0 2	Н	(IQR)	111 2 0 2	Н			
Distortions									
Frontal	3(2-3)	2.6 ± 0.6	1/3	0(0-0)	0.0 ± 0.0	0/0	<		
Trontar	0 (2 0)	2.0 2 0.0	1,0	0 (0 0)	0.0 = 0.0	0,0	0.001		
Frontobasal	3(2-3)	2.7 ± 0.5	2/3	0(0-0)	0.0 ± 0.0	0/0	<		
	, ,		, -	- ()		-, -	0.001		
Temporopolar	3 (2.5 –	2.8 ± 0.4	2/3	0(0-0)	0.0 ± 0.0	0/0	<		
1 1	3)		·	` /		·	0.001		
Infratentorial	1(1-1)	1.1 ± 0.3	1/2	0(0-0)	0.0 ± 0.0	0/0	< 0.001		
Dulastila (lassa							0.001		
Pulsatile flow									
infratentorial	1(1-4)	2.2 ± 1.6	0/4	3(3-4)	3.4 ± 0.7	2/4	0.02		
supratentorial	1(0-1)	0.7 ± 0.8	0/3	0(0-0)	0.0 ± 0.0	0/0	0.004		
Chemical shift									
Frontal	0(0-0)	0.1 ± 0.3	0/1	0(0-0)	0.0 ± 0.0	0/0	0.16		
Residual Aliasing									
Central	0(0-0)	0.2 ± 0.6	0/2	0(0-0)	0.0 ± 0.0	0/0	0.10		
Spikes ¹	0(0-1)	0.4 ± 0.6	0/2	0(0-0)	0.0 ± 0.0	0/0	0.03		
Subject motion	0(0-0)	0.0 ± 0.0	0/0	0(0-0)	0.1 ± 0.2	0/1	0.32		

Note. N = 17. Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = lowest value. All artifacts were rated on an ordinal five-point Likert scale: 0 = no artifact; 1 = artifact exists, but diagnostic information is not limited; 2 = artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = artifact exists, and diagnostic information is limited in the artifact region; 4 = artifact exists, and diagnostic information is severely limited in the artifact region. The p-values were calculated using the Wilcoxon signed-rank test. 1 = artifact In the case of a positive rating, artifacts only occurred in one single image slice each.




Figure 15. Infratentorial pulsatile flow artifacts that severely limit diagnostic information in the FLAIR_{UF} images and the FLAIR_{3Da} images. (a) FLAIR_{UF} (left) and FLAIR_{3Da} as a reference (right), cerebellum: The continuous arrows depict an inflammatory true positive lesion (approx. 4 mm × 3 mm). The dotted arrow indicates a pulsation artifact that is prone to being confused with a lesion. It was counted as a small, false positive lesion (approx. 2 mm × 1 mm). The arrowhead points to a pulsation artifact that is not likely to be confused with a lesion due to its typical location adjacent to the occipital sinus. (b) FLAIR_{3Da} (left) and FLAIR_{UF} as a reference (right), at the level of the pons: Top images: Typical hyperintense artifact band in the FLAIR_{3Da} image; the arrowhead points to an intensely hyperintense spot within the artifact region that is part of the grainy texture of the artifact. Possible lesions within the artifact region would have been masked completely. Middle images: the continuous arrows show a large lesion (approx. 8 mm × 3 mm) that was misinterpreted as part of the pulsation artifact in the FLAIR_{3Da} image. Bottom images: The dotted arrow denotes a small, false positive FLAIR_{3Da} lesion (approx. 2 mm × 2 mm) that turned out to be part of the pulsation artifact. Note. Corresponding slices could not be positioned exactly identically owing to different slice thicknesses including slice gaps and non-parallel slice inclinations.




Figure 16. Minor artifacts in the FLAIRuf images. (a) Supratentorial pulsation artifacts, caused by extracerebral blood vessels: hyperintense (left image) or hypointense (right image). Hyperintense artifacts can usually be distinguished easily from a lesion, owing to its well-defined, sharply demarcated margin in relation to its size. Hyperintense and hypointense artifacts can usually be related to distant blood vessels, shifted along the phase encoding direction at fixed intervals corresponding to k-space sampling patterns (a quarter of the field of view for the protocol used in our study). Hyperintense artifacts are often located directly adjacent to hypointense artifacts in neighboring image slices. (b) Rare chemical shift artifacts due to incomplete fat suppression, in the shape of hyperintense (left image) or hypointense (right image) frontal streaks. (c) Rare residual aliasing, in the shape of a subtle hyperintense right central streak. (d) Rare spike artifacts, appearing in a herringbone pattern. (e) Supratentorial pulsation artifacts, caused by parenchymal blood vessels (singular findings): hyperintense (small FP lesion), insular cortex (left image) and hypointense, anterior limb of internal capsule (right image). They could not be distinguished using the FLAIR3D sequence, however, clearly correlated with contrast-enhanced images. Also, note the ventricular cerebrospinal fluid pulsation artifact in the right image.

Finally, it must be pointed out that all analyses were confined to the brain parenchyma. The subarachnoid space, the dura mater, the cranium, and the scalp, along with other parts of the head such as the nasal cavity and the paranasal sinuses, the internal and external ear, the oral cavity, the throat, the eyes, the orbits, the cranial nerves, muscles, adipose tissue, and other osseous or chondral structures, are insufficiently delineated in the FLAIRUF images, as can be seen in the image examples.

3.3.2. FLAIRUF Compared with FLAIRTSE

SNR and CNR were rated relatively similar in the FLAIR_{UF} and FLAIR_{TSE} images (see Table 16). However, the low number of paired slice series only serves to provide a rough orientation. Results are overall ratings of the slice series, and positional dependences of SNR and CNR (as demonstrated in Section 3.3.3) seem to be similar in the FLAIR_{UF} and FLAIR_{TSE} images.

Table 16. SNR and CNR in FLAIRuf and FLAIRtse images.

D1	I	FLAIRUF		FLAIRTSE				
Parameter	Mdn (IQR)	$M \pm SD$	L/H	Mdn (IÇ	(R) M±SD	L/H		
SNR	3 (3 – 3)	3.00 ± 0.00	3/3	3 (3 – 3	3.00 \pm 0.00	3/3		
CNR	3(2.5-3)	2.67 ± 0.58	2/3	2(2-2)	2.00 ± 0.00	2/2		

Note. N = 3. SNR = signal-to-noise ratio; CNR = contrast-to-noise ratio; Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. Both parameters were rated on an ordinal five-point Likert scale: 1 = very good; 2 = good; 3 = acceptable; 4 = mediocre/diagnostic; 5 = poor/non-diagnostic. Significance testing was omitted due to the low number of cases.

Artifacts in the FLAIR_{UF} and FLAIR_{TSE} images are contrasted in Table 17. Again, the small amount of data provides only a rough impression. FLAIR_{UF} results are specified in greater detail in

Section 3.3.1. Relevant artifacts in the FLAIR_{TSE} images that have the potential to significantly limit diagnostic information are infratentorial pulsatile flow artifacts, either by masking or mimicking lesions. Typically, they appeared as a streaky, irregular (hyperintense and hypointense) band across the middle of the cerebellum, between the right and left sigmoid sinuses (see Figure 17).




Figure 17. Infratentorial pulsatile flow artifacts in FLAIRTSE (left), contrasted with corresponding FLAIRUF slices (right). The artifact regions are marked with dotted arrows. They appear as irregular, streaky bands traversing the cerebellum from the right sigmoid sinus to the left sigmoid sinus. (**a**) Artifact-induced hyper- and hypointense dots across the cerebellum; the FLAIRUF image confirms that there is no actual lesion in this area. (**b**) Artifact-induced hyper- and hypointense streaks across the cerebellum; the FLAIRUF image confirms that there is one actual lesion (continuous arrow) in this area. Note. Corresponding slices could not be positioned exactly identically owing to different slice intervals and non-parallel slice inclinations.

Table 17. Artifacts in the FLAIRUF and FLAIRTSE images.

F	LAIRuf		FLAIRTSE				
Mdn (IQR)	$M \pm SD$	L/H	Mdn (IQR)	$M \pm SD$	L/H		
					_		
3(3-3)	3.0 ± 0.0	3/3	0(0-0)	0.0 ± 0.0	0/0		
3(3-3)	3.0 ± 0.0	3/3	0(0-0)	0.0 ± 0.0	0/0		
3(3-3)	3.0 ± 0.0	3/3	0(0-0)	0.0 ± 0.0	0/0		
1(1-1)	1.0 ± 0.0	1/1	0(0-0)	0.0 ± 0.0	0/0		
1(1-1)	1.0 ± 0.0	1/1	2(1.5-3)	2.3 ± 1.5	1/4		
0(0-0)	0.0 ± 0.0	0/0	0(0-0.5)	0.3 ± 0.6	0/1		
0(0-0)	0.0 ± 0.0	0/0	0(0-0)	0.0 ± 0.0	0/0		
0(0-1)	0.7 ± 1.2	0/2	0(0-0)	0.0 ± 0.0	0/0		
0(0-0.5)	0.3 ± 0.6	0/1	0(0-0)	0.0 ± 0.0	0/0		
0(0-0)	0.0 ± 0.0	0/0	0(0-0.5)	0.3 ± 0.6	0/1		
	Mdn (IQR) 3 (3-3) 3 (3-3) 1 (1-1) 1 (1-1) 0 (0-0) 0 (0-1) 0 (0-0.5)	$3 (3-3) \qquad 3.0 \pm 0.0$ $3 (3-3) \qquad 3.0 \pm 0.0$ $3 (3-3) \qquad 3.0 \pm 0.0$ $1 (1-1) \qquad 1.0 \pm 0.0$ $1 (1-1) \qquad 1.0 \pm 0.0$ $0 (0-0) \qquad 0.0 \pm 0.0$ $0 (0-1) \qquad 0.7 \pm 1.2$ $0 (0-0.5) \qquad 0.3 \pm 0.6$	Mdn (IQR) $M \pm SD$ L/H $3 (3-3)$ 3.0 ± 0.0 $3/3$ $3 (3-3)$ 3.0 ± 0.0 $3/3$ $3 (3-3)$ 3.0 ± 0.0 $3/3$ $1 (1-1)$ 1.0 ± 0.0 $1/1$ $1 (1-1)$ 1.0 ± 0.0 $1/1$ $0 (0-0)$ 0.0 ± 0.0 $0/0$ $0 (0-0)$ 0.0 ± 0.0 $0/0$ $0 (0-1)$ 0.7 ± 1.2 $0/2$ $0 (0-0.5)$ 0.3 ± 0.6 $0/1$	Mdn (IQR) $M \pm SD$ L/H Mdn (IQR) $3 (3-3)$ 3.0 ± 0.0 $3/3$ $0 (0-0)$ $3 (3-3)$ 3.0 ± 0.0 $3/3$ $0 (0-0)$ $3 (3-3)$ 3.0 ± 0.0 $3/3$ $0 (0-0)$ $1 (1-1)$ 1.0 ± 0.0 $1/1$ $0 (0-0)$ $1 (1-1)$ 1.0 ± 0.0 $1/1$ $2 (1.5-3)$ $0 (0-0)$ 0.0 ± 0.0 $0/0$ $0 (0-0.5)$ $0 (0-0)$ 0.0 ± 0.0 $0/0$ $0 (0-0)$ $0 (0-1)$ 0.7 ± 1.2 $0/2$ $0 (0-0)$ $0 (0-0.5)$ 0.3 ± 0.6 $0/1$ $0 (0-0)$	Mdn (IQR) M ± SD L/H Mdn (IQR) M ± SD 3 (3-3) 3.0 ± 0.0 $3/3$ $0 (0-0)$ 0.0 ± 0.0 3 (3-3) 3.0 ± 0.0 $3/3$ $0 (0-0)$ 0.0 ± 0.0 1 (1-1) 1.0 ± 0.0 $1/1$ $0 (0-0)$ 0.0 ± 0.0 1 (1-1) 1.0 ± 0.0 $1/1$ $2 (1.5-3)$ 2.3 ± 1.5 0 (0-0) 0.0 ± 0.0 $0/0$ $0 (0-0.5)$ 0.3 ± 0.6 0 (0-0) 0.0 ± 0.0 $0/0$ $0 (0-0)$ 0.0 ± 0.0 0 (0-0.5) 0.3 ± 0.6 $0/1$ $0 (0-0)$ 0.0 ± 0.0		

Note. N = 3. Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. All artifacts were rated on an ordinal five-point Likert scale: 0 = no artifact; 1 = artifact exists, but diagnostic information is not limited; 2 = artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = artifact exists, and diagnostic information is severely limited in the artifact region. Significance testing was omitted due to the low number of cases. 1 = artifact region, artifacts only occurred in one single image slice each.

3.3.3. Positional dependence of SNR and CNR in FLAIRUF

In the FLAIRuf images, the vicinity of each TPcs lesion was rated for relative SNR and CNR levels (substandard or standard/superior; with reference to the average FLAIRuf image quality). Tables 18 and 19 present the results grouped by brain regions. Within a region, lesion-rich areas are given more weight than lesion-poor areas. Compared to all the other brain regions, the SNR appeared significantly reduced in central and infratentorial brain regions (p < 0.001), and the CNR appeared significantly lower in infratentorial brain regions (p < 0.001). What is not evident from the data and is a distinctive characteristic of the infratentorial region is the highly uneven distribution of SNR levels across this area: From highly substandard (in central areas such as the pons) to highly above the average (in peripheral areas such as the posterior lobe of the cerebellum). The CNR, however, appeared to be reduced all over the infratentorial areas, particularly the fine folium-sulcus texture of the cerebellum could not be distinguished sufficiently. Image examples are given in Figure 18.

Table 18. FLAIRUF: SNR assessment in the vicinity of TPGS lesions, categorized by location.

	SNR sub	standard		Yes Percentage			
Location	Yes	No	TPGS	95% CI [LL, UL]		p	
	п	п	п	%			
All	147	421	568	25.9 [22.3, 29.7]			
Frontal	27	163	190	14.2 [9.6, 20.0]			
Parietal	29	91	120	24.2 [16.8, 32.8]			0.07
Temporal	24	111	135	17.8 [11.7, 25.3]		< 0.001	0.07
Occipital	1	17	18	5.6 [0.1, 27.3]		< 0.001	
Central	35	19	54	64.8 [50.6, 77.3]			0.67
Infratentorial	31	20	51	60.8 [46.1, 74.2]			0.67
Frontal & Parietal &	01	202	462	17 5 [14 1 01 0]			
Temporal & Occipital	81	382	463	17.5 [14.1, 21.3]	-	< 0.001	
Central & Infratentorial	66	39	105	62.9 [52.9, 72.1]			

Note. SNR = signal-to-noise ratio; TPGs = true positive lesion counts using the gold standard; CI = confidence interval (Clopper-Pearson); LL = lower limit; UL = upper limit. Brain regions as in Table 11. The p-values were calculated using the chi-squared test.

Table 19. FLAIRuf: CNR assessment in the vicinity of TPcs lesions, categorized by location.

	Cl	٧R		Yes				
	substa	ındard	_	Percentage				
Location	Yes	No	TPGS	95% CI [LL,	р			
Location		110		UL]				
	n	п	п	%				
All	33	535	568	5.8 [4.0, 8.1]	_			
Frontal	6	184	190	3.2 [1.2, 6.8]	\neg			
Parietal	7	113	120	5.8 [2.4, 11.6]				
Temporal	2	133	135	1.5 [0.2, 5.2]			- 0.15	
Occipital	0	18	18	0.0 [0.0, 18.5]	_	< 0.001		
Central	0	54	54	0.0 [0.0, 6.6]		0.001		
To free to m to min!	10	22	E1	35.3 [22.4,				
Infratentorial	18	33	51	49.9]				
Frontal & Parietal &								
Temporal &	15	502	517	2.9 [1.6, 4.7]		<		
Occipital & Central					_	0.001		
Infratentorial	18	33	51	35.3 [22.4,		0.001		
mmatemonal	10	55	31	49.9]				

Note. CNR = contrast-to-noise ratio; further abbreviations as in Table 18. Brain regions as in Table 11. The p-values were calculated using the chi-squared test. ¹ Insular lobe, corpus callosum, basal nuclei, and diencephalon. ² Brainstem and cerebellum.




Figure 18. Positional dependence of SNR and CNR within the FLAIRuF images. (a) Image slice at the level of the basal nuclei. The SNR deteriorates towards the center of the image, whereas the CNR remains relatively good. Note that both the SNR and CNR are excellent in the marginal regions of the cerebral cortex, e.g., in the occipital lobe. (b) Image slice at the level of the pons and the cerebellum. The SNR is substandard around the pons and improves exceedingly towards the posterior lobe of the

cerebellum to an excellent level. The CNR, however, seems generally slightly substandard in this area compared to other brain regions, even in the most posterior regions. This may be associated with the characteristic, fine folium-sulcus texture of the cerebellum (e.g., vermis or posterior lobe), which cannot be distinguished clearly.

4. Discussion

4.1. Main Findings of This Study

This study investigated an ultrafast axial DL-enhanced EPI-FLAIR (FLAIRUF) MRI sequence in RRMS patients. The FLAIRUF sequence reduced the acquisition time to almost a sixth of the time required for conventional three-dimensional FLAIR (FLAIR3D) acquisitions and nearly a third of the time required for axial standard TSE-FLAIR (FLAIRTSE) acquisitions. With regard to the detection of inflammatory brain lesions, we did not observe any significant differences between the FLAIRUF images and the FLAIR3Da images in either sensitivity for wide large lesions (≥ 3 mm $\times \geq 2$ mm) or PPV for all large lesions (≥ 3 mm total) despite high lesion numbers. The same applies to the sensitivity of large lesion detection (≥ 3 mm total) in the FLAIRUF images compared to the FLAIRTSE images. Lesion conspicuity did not differ significantly between brain regions in the FLAIRUF images, except for occipital large lesions (superior results) and central large lesions (inferior results). To our knowledge, this study represents the first in-depth quantitative and qualitative evaluation of inflammatory lesions using a DL-enhanced EPI-FLAIR sequence.

4.2. Significance of MRI and Ultrafast MRI

In MS patients, severity of the clinical course is influenced by the start and choice of disease-modifying therapy (DMT). Notably, early treatment start or treatment escalation delays disease progress of both clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) in particular [67]. To decide on adequate therapeutic strategies depending on disease activity, MRI plays a major role [10,67,68]. McDonald diagnostic criteria are based on number, location, and size of lesions as well as temporal changes of lesions [6–9]. A lesion size of over 3 millimeters is deemed to be appropriate to account for the diagnostic criteria [14]. In order to adapt DMT without delay, specific monitoring intervals are recommended [10]. Notably, CIS patients benefit from very tight follow-up MRI examinations, particularly during the first year [10,69]. Nonetheless, overall MRI scan capacity is far from enough to satisfy demand in numerous parts of the world, and waiting times usually exceed the maximum recommended time, thus worsening medical outcomes and increasing the economic costs [70–75]. Against this background, utilizing DL-enhanced EPI-FLAIR sequences may be a promising approach to ameliorate treatment quality while at the same time meeting diagnostic requirements.

4.3. Limitations of the FLAIRuf Images

Despite its remarkable capabilities, the FLAIRuf images still have three primary limitations. First, lesion size is a limiting factor for the FLAIRuf images, particularly in comparison with the FLAIRad images. Almost every second small lesion (< 3 mm) and more than every fifth narrow large lesion (≥ 3 mm $\times < 2$ mm) could not be detected using the FLAIRuf images. Additionally, out of all presumed small lesions (< 3 mm), about a quarter detected using the ultrafast sequence variant were false-positives. There may be one main cause of those limitations: the relatively large slice thickness including slice gaps in this context. It should be noted that this parameter did even influence the detection of large lesions (≥ 3 mm).

Secondly, lesion location may represent another limiting factor in the FLAIRUF images. There are several location-dependent factors: 1) SNR deterioration towards the central regions of the images, and simultaneously, SNR enhancement towards marginal regions such as the occipital lobe (even though it appears similar compared with the FLAIRUFE images); 2) some limits of CNR, which primarily become apparent when depicting regions that require high spatial resolution and low slice thickness, particularly the cerebellum with its fine folium-sulcus texture (even though the overall

CNR only seems marginally reduced compared with the FLAIR_{TSE} images); 3) pulsatile flow artifacts, which mostly affect image quality by mimicking infratentorial lesions (even though infratentorial pulsation artifacts appear to limit image quality to a similar extent using FLAIR_{3Da} or FLAIR_{TSE}, mostly by masking potential lesions); 4) spatial distortion artifacts (frontal, frontobasal, temporopolar, and infratentorial), which may conceal potential lesions; 5) relatively large slice thickness including slice gaps, which may hinder the distinction between lesions and physiological brain structures at certain locations, particularly near the cortex.

Thirdly, there is an additional limitation apart from those associated with lesion assessment: most structures outside the parenchyma are insufficiently delineated in the FLAIRur images, such as osseus structures, air-containing structures, or adipose tissue. Reasons for this may be susceptibility artifacts and fat suppression. However, the optic nerves, for example, are clearly distinguishable, and fat suppression might even be advantageous in terms of assessing optic neuritis. Though, this remains speculative and beyond the scope of our study.

4.4. Considerations on Ratings for Lesion Conspicuity in FLAIRuf

Ratings for lesion conspicuity in FLAIR_{UF} (Section 3.2.3) were intended to compare results among the brain regions within the FLAIR_{UF} images. Since a kind of reference was required (FLAIR_{3Da}), the ratings appear to be biased by position-dependent lesion conspicuity in FLAIR_{3Da}. However, those potential position-dependent differences did not exist at all in the FLAIR_{3Da} images, and image quality was excellent across all regions. The only exception was infratentorial, where a few lesions were masked by pulsation artifacts (FN lesions); all the other infratentorial lesions were not affected in any way. In order to prevent FLAIR_{3Da}-biased (infratentorial) conspicuity ratings in FLAIR_{UF}, assessments were confined to TP_{3Da} lesions instead of TP_{CS} lesions.

As stated previously, the conspicuity ratings do not seem to be biased by lesion size variations among the brain regions, with one exception: ratings of infratentorial large lesions might have been biased towards falsely positive results, since the proportion of wide lesions to narrow lesions was greater compared to all the other regions, while at the same time, the conspicuity ratings appeared to be superior for wide lesions. That might be an explanation for why the conspicuity ratings do not reflect the substandard SNR and CNR ratings for this region. That discrepancy did not exist in other locations.

Finally, localization-dependent conspicuity results in FLAIR_{UF} could only be demonstrated for large lesions, not for small lesions. The underlying cause could be slice thickness and slice gaps to be the limiting factors for small lesion conspicuity, which is independent of the position. SNR-related positional dependence appears to have a subordinate role in this context. For instance, large central lesions stood out with a comparatively high proportion of grade 3 ratings (conspicuity better in the FLAIR_{3Da} images but classified as a lesion using only the FLAIR_{UF} images), but for small central lesions, that proportion was relatively low in favor of grade 4 and 5 ratings (not classified as a lesion using FLAIR_{UF}). In all the other brain regions, on the contrary, large lesions predominantly exhibited grade 1 and 2 ratings (conspicuity at least equal in the FLAIR_{UF} images), i.e., comparatively small proportions of grade 3 ratings, while for small lesions, that proportion was considerably lower in favor of grade 4 and 5 ratings, comparable to the central small lesion group. However, for occipital and infratentorial small lesions, the counts were insufficient to draw further conclusions regarding position-dependent conspicuity of small lesions.

4.5. Outcomes Correlated with Technical Features

The above-mentioned characteristics of the FLAIR_{UF} images arise from specific sequence properties. To begin with, there is a correlation between slice thickness (slice gap included) and visibility of small lesions: if the lesion size is smaller than the slice thickness, signal intensity will decrease and with it the lesion contrast due to the partial volume effect. At some point, the lesion signal will disappear completely if lesions are too small. Thus, there is a direct correlation between that threshold and slice thickness.

Apart from the partial volume effect, EPI-related CNR loss seems to be sufficiently counterbalanced by MT preparation [62]. Here, MT pulses serve as saturation pulses selectively affecting macromolecular protons and adjacent water molecules to enhance image contrast [76].

In EPI, the SNR is diminished due to substantial signal loss during its long echo train, and lack of refocusing pulses combined with rapid T2* signal decay. Nevertheless, aided by the DL reconstruction, the SNR in FLAIR_{UF} appeared similar compared to FLAIR_{TSE}. In both image variants, the SNR (and related lesion conspicuity) decreased similarly towards the center of the image, owing to coil dependency in PI [77–79]. Accordingly, there is an inversely proportional relationship between SNR and the geometry (g)-factor [77–79]. This factor is affected by coil sensitivity and voxel location, usually exhibiting the greatest values in the center of the image [77–79]. Although the DL reconstruction method was designed to compensate for this specific factor, its SNR gains were eventually limited, especially in combination with stringent requirements for slice thickness. In contrast, the excellent SNR in FLAIR_{3D} can be attributed to the fact that in 3D acquisitions, the complete volume is excited with each shot.

Besides, the long readout duration in EPI has another significant impact on image quality (together with the very low pixel bandwidth along the phase-encoding direction in EPI): increased sensitivity to susceptibility artifacts [80]. If a substance is located in an external homogeneous magnetic field, the magnetic field lines will either be dispersed (e.g., bone tissue) or concentrated (e.g., air or metal) around that material, depending on its susceptibility properties [81]. Consequently, the magnetic field is disturbed in areas where susceptibility differences are large (e.g., air-filled bones), leading to an accelerated phase coherence loss and T2* signal decay, on the one hand, and accumulation of phase errors along with positioning errors in the phase encoding direction, on the other [2]. This explains the appearance of both distortion artifacts, particularly arising in the vicinity of air-tissue interfaces in the phase encoding direction, and signal decrease in tissues surrounding the brain parenchyma, caused by differences in magnetic susceptibility. In strong magnetic fields, susceptibility differences further increase, and phase incoherences accumulate to a greater extent over the duration of the echo train [2,82,83]. In contrast, SNR, CNR, spatial resolution and scan time benefit from a strong magnetic field strength [82,83].

Apart from susceptibility effects, there is another reason for signal decrease in non-parenchymal tissues in FLAIRuff: fat-suppression. It is essential for low-segmented EPI in order to avert chemical shift artifacts [2]. Those artifacts derive from spatial signal misregistration owing to frequency differences between protons in fat and water. Without fat-suppression, however, the implicitly low pixel bandwidth along the phase-encoding direction in EPI would lead to accumulation of phase shifts between fat and water, resulting in chemical shift artifacts in the phase encoding direction [80,84]. With singular exceptions located close to the frontal air-tissue interfaces, we did not observe any chemical shift artifacts caused by incomplete fat suppression in the FLAIRuff images.

In addition, we observed other artifacts caused by phase errors: pulsatile flow artifacts. They usually occur along the phase encoding direction [85]. Accordingly, we were able to relate most artifacts to structures containing flowing blood or liquor in all three image variants (FLAIR_{UF}, FLAIR_{TSE}, and FLAIR_{3Da}), each of them revealing distinctive characteristics. Typically, the artifacts either occurred around blood vessels, particularly around infratentorial venous sinuses (FLAIR_{UF}), or they were aligned in positions shifted from blood vessels along the phase encoding direction (FLAIR_{UF}, FLAIR_{3Da}, and FLAIR_{TSE}). In the FLAIR_{UF} and FLAIR_{3Da} images, artifacts were shifted along the anterior-posterior axis, while in the FLAIR_{TSE} images, artifacts were shifted along the left-right axis (compare Table 2). In the FLAIR_{UF} images, replicas were shifted at intervals of a quarter of the field of view (according to the PI acceleration factor of two and the two-segmented k-space). In the FLAIR_{3Da} and FLAIR_{TSE} images, artifacts manifested as grainy or streaky bands. However, in terms of limitations of diagnostic information caused by pulsation artifacts, the FLAIR_{UF} images were not inferior.

Finally, there were three more rare minor artifacts, two of which could be seen in the FLAIRUF images: residual aliasing and spike artifacts. The former is related to PI reconstruction, and the latter is related to the rapid switching of gradients in EPI. The third artifact type, minor motion artifacts

caused by subject movement, could not be observed in the FLAIRUF images, but in one FLAIR $_{3Da}$ and one FLAIR $_{3Da}$ and FLAIR $_{3Da}$

4.6. Limitations of the Study

There are some limitations of this study that might have affected our results. To begin with, the methodological approach may be associated with some selection bias. Examinations were carried out using one specific scanner, and the patient sample may be biased by common appointment scheduling practices in terms of disease manifestation or severity (medium or low disease activity in an outpatient follow-up setting). Although no patient declined to participate in the study, there were a couple of patients that could not be included from the outset due to the associated additional expenditure of time. That probably led to further sampling bias (e.g., age, sex, clinical condition). In particular, the sex ratio in our study was atypical (compare Sections 1 and 2.1). Aside from selection bias, there were more factors limiting the external validity, such as the single-center study design using only one single 3 T MRI scanner from one specific manufacturer.

Moreover, there might have been some observer bias inherent to this study, despite all efforts and critical appraisal. In this regard, implementing image blinding would not have had a positive effect due to the significantly different and easily distinguishable nature of the images, and the study was designed for subjective side-by-side comparisons. Generally, radiological readers' assessments may also depend on their level of experience with the FLAIRup image characteristics.

Even though the number of participants was modest, the lesion counts were substantial, providing high statistical power. Nevertheless, there is an important limitation from a statistical point of view: Statistically, several lesions within one subject are no independent observations, because they are bound to both the same individual and time of scan. Accordingly, lesion conspicuity could possibly have been influenced by parameters that might have varied among the individuals or scans, which may have induced statistical bias. Also, non-significant test results are indications, but not proof of equality. So, in large part, the results of the study are indicative, not conclusive. However, variances among the image data appeared to play a minor role, at most, and non-significant results are more meaningful when based on a large sample size. Methodologically, it would have been precise either to rate all lesions from one image series as a whole or to randomly select and analyze only one lesion from each image series after recording all existing lesions. However, the former procedure would have provided highly inaccurate outcomes, and the latter procedure would have provided relatively meaningless test results (if statistically non-significant), owing to the sample size. In this study, the small FLAIRTSE sample size only provides indicative findings: results were either statistically tested, accepting the possibility of an increased type II error, or statistical testing was omitted.

In the future, further prospective studies and confirmatory trials with larger numbers of participants and more diverse cohorts, various scanners, and modified reconstruction and acquisition methods need to be conducted. Further radiological reading should possibly include separate image assessments instead of side-by-side comparisons. Plus, other studies covering MS patients might consider additional contrasts (e.g., contrast enhanced T1w sequences), orientations (sagittal, coronal), or regions (such as the spine or the optic nerves).

4.7. Future Perspectives

All in all, our results suggest that FLAIR_{UF} may be an appropriate approach for assessing cerebral inflammatory lesions. Diagnostic performance did not prove inferior compared to conventional FLAIR_{3D} in terms of MS lesion detection (≥ 3 mm $\times \geq 2$ mm) in just about a sixth of the time. This demonstrates the tremendous progress made in the field of EPI. In the light of extensive waiting times for MR examinations and patient-dependent constraints to carry them out, for example claustrophobia or inability to remain motionless (i.e., children or disease- and age-related obstacles), ultrafast imaging seems an essential tool. However, there are still some challenges to overcome in

refining this technique while aiming to combine high resolution with high SNR at high field strengths along with low artifacts.

5. Conclusions

In conclusion, this study indicates that ultrafast DL-enhanced EPI-FLAIR might be an appropriate method for the assessment of cerebral inflammatory lesions (≥ 3 mm) in MS. Apart from relatively minor limitations regarding lesion size and lesion location, it did not prove inferior to conventional FLAIR methods in the main, while being conducted in a fraction of time. In consideration of both MRI waiting times and patients that cannot remain motionless in the scanner for long, EPI might be an expedient alternative to conventional imaging. However, further studies are required to confirm our findings.

Author Contributions: Conceptualization, M.S. and B.B.; methodology, M.S. and B.B.; software, T.F. and B.C.; validation, M.S. and B.B.; formal analysis, M.S. and B.B.; investigation, M.S., C.R., E.B., M.K. and B.B.; resources, M.K.; data curation, M.S.; writing—original draft preparation, M.S.; writing—review and editing, M.S., C.R., E.B., T.F., B.C., M.K. and B.B.; visualization, M.S.; supervision, B.B.; project administration, B.B. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the Open Access Publication Fund of the University of Tuebingen.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Medical Faculty of the Eberhard Karls University and the University Hospital of Tuebingen, Germany (reference number 031/2021BO2, approved on 27 April 2021).

Informed Consent Statement: Informed consent for participation in the study, for publication of the results and sharing of anonymized data was obtained from all subjects prior to acquisition of any data.

Data Availability Statement: Anonymized, defaced MRI data can be obtained by the corresponding author upon reasonable request.

Acknowledgments: The authors would like to thank Silke Buschbach for technical support in acquiring the images and data management.

Conflicts of Interest: M.S., C.R. and E.B. declare no conflict of interest. The software prototype used in the study was provided by Siemens Healthineers AG. T.F. is an employee of Siemens Healthineers, owns stocks of Siemens (Healthineers) AG and holds patents filed by Siemens (Healthineers). B.C. is an employee of Siemens Medical Solutions, USA, and holds patents filed by Siemens (Healthineers). M.K. has served on advisory boards and received speaker fees/travel grants from Merck, Sanofi-Genzyme, Novartis, Biogen, Janssen, Alexion, Celgene/Bristol-Myers Squibb, and Roche. He has received research grants from Merck, Roche, Novartis, Sanofi-Genzyme, and Celgene/Bristol-Myers Squibb. B.B. is co-founder, shareholder, and CTO of AIRAmed GmbH. The Open Access Publication Fund had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

- 1. Mansfield, P. Multi-planar image formation using NMR spin echoes. *J. Phys. C: Solid State Phys.* **1977**, 10, L55-L58, doi:10.1088/0022-3719/10/3/004.
- 2. Poustchi-Amin, M.; Mirowitz, S.A.; Brown, J.J.; McKinstry, R.C.; Li, T. Principles and applications of echoplanar imaging: a review for the general radiologist. *Radiographics* **2001**, 21, 767–779, doi:10.1148/radiographics.21.3.g01ma23767.
- 3. Kinoshita, T.; Okudera, T.; Tamura, H.; Ogawa, T.; Hatazawa, J. Assessment of Lacunar Hemorrhage Associated With Hypertensive Stroke by Echo-Planar Gradient-Echo T2*-Weighted MRI. *Stroke* **2000**, *31*, 1646–1650, doi:10.1161/01.STR.31.7.1646.
- 4. Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502–1517, doi:10.1016/S0140-6736(08)61620-7.
- 5. Leray, E.; Moreau, T.; Fromont, A.; Edan, G. Epidemiology of multiple sclerosis. *Rev. Neurol. (Paris)* **2016**, 172, 3–13, doi:10.1016/j.neurol.2015.10.006.
- McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann. Neurol.* 2001, 50, 121– 127, doi:10.1002/ana.1032.

- 7. Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.-P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O'Connor, P.W.; et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann. Neurol.* 2005, 58, 840–846, doi:10.1002/ana.20703.
- 8. Polman, C.H.; Reingold, S.C.; Banwell, B.; Clanet, M.; Cohen, J.A.; Filippi, M.; Fujihara, K.; Havrdova, E.; Hutchinson, M.; Kappos, L.; et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Ann. Neurol.* **2011**, *69*, 292–302, doi:10.1002/ana.22366.
- 9. Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* **2018**, *17*, 162–173, doi:10.1016/S1474-4422(17)30470-2.
- 10. Kaunzner, U.W.; Gauthier, S.A. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. *Ther. Adv. Neurol. Disord.* **2017**, *10*, 247–261, doi:10.1177/1756285617708911.
- 11. Filippi, M.; Rocca, M.A.; Wiessmann, M.; Mennea, S.; Cercignani, M.; Yousry, T.A.; Sormani, M.P.; Comi, G. A Comparison of MR Imaging with Fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR Sequences in the Assessment of Patients with Multiple Sclerosis. *AJNR Am. J. Neuroradiol.* **1999**, 20, 1931–1938.
- 12. Gebarski, S.S.; Gabrielsen, T.O.; Gilman, S.; Knake, J.E.; Latack, J.T.; Aisen, A.M. The initial diagnosis of multiple sclerosis: clinical impact of magnetic resonance imaging. *Ann. Neurol.* **1985**, *17*, 469–474, doi:10.1002/ana.410170509.
- 13. Barkhof, F.; Filippi, M.; Miller, D.H.; Scheltens, P.; Campi, A.; Polman, C.H.; Comi, G.; Adèr, H.J.; Losseff, N.; Valk, J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. *Brain* 1997, 120, 2059–2069, doi:10.1093/brain/120.11.2059.
- 14. Grahl, S.; Pongratz, V.; Schmidt, P.; Engl, C.; Bussas, M.; Radetz, A.; Gonzalez-Escamilla, G.; Groppa, S.; Zipp, F.; Lukas, C.; et al. Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. *Mult. Scler. Relat. Disord.* **2019**, 29, 124–129, doi:10.1016/j.msard.2019.01.042.
- 15. Selvikvåg Lundervold, A.; Lundervold, A. An overview of deep learning in medical imaging focusing on MRI. *Z. Med. Phys.* **2019**, 29, 102–127, doi:10.1016/j.zemedi.2018.11.002.
- Radmanesh, A.; Muckley, M.J.; Murrell, T.; Lindsey, E.; Sriram, A.; Knoll, F.; Sodickson, D.K.; Lui, Y.W. Exploring the Acceleration Limits of Deep Learning Variational Network–based Two-dimensional Brain MRI. *Radiol. Artif. Intell.* 2022, 4, e210313:1-e210313:11, doi:10.1148/ryai.210313.
- 17. Mani, A.; Santini, T.; Puppala, R.; Dahl, M.; Venkatesh, S.; Walker, E.; DeHaven, M.; Isitan, C.; Ibrahim, T.S.; Wang, L.; et al. Applying Deep Learning to Accelerated Clinical Brain Magnetic Resonance Imaging for Multiple Sclerosis. *Front. Neurol.* **2021**, *12*, doi:10.3389/fneur.2021.685276.
- 18. Estler, A.; Hauser, T.-K.; Mengel, A.; Brunnée, M.; Zerweck, L.; Richter, V.; Zuena, M.; Schuhholz, M.; Ernemann, U.; Gohla, G. Deep Learning Accelerated Image Reconstruction of Fluid-Attenuated Inversion Recovery Sequence in Brain Imaging: Reduction of Acquisition Time and Improvement of Image Quality. *Acad. Radiol.* **2024**, *31*, 180–186, doi:10.1016/j.acra.2023.05.010.
- 19. Iwamura, M.; Ide, S.; Sato, K.; Kakuta, A.; Tatsuo, S.; Nozaki, A.; Wakayama, T.; Ueno, T.; Haga, R.; Kakizaki, M.; et al. Thin-slice Two-dimensional T2-weighted Imaging with Deep Learning-based Reconstruction: Improved Lesion Detection in the Brain of Patients with Multiple Sclerosis. *Magn. Reson. Med. Sci.* 2024, 23, 184–192, doi:10.2463/mrms.mp.2022-0112.
- 20. Toledano-Massiah, S.; Sayadi, A.; Boer, R. de; Gelderblom, J.; Mahdjoub, R.; Gerber, S.; Zuber, M.; Zins, M.; Hodel, J. Accuracy of the Compressed Sensing Accelerated 3D-FLAIR Sequence for the Detection of MS Plaques at 3T. *AJNR Am. J. Neuroradiol.* **2018**, *39*, 454–458, doi:10.3174/ajnr.A5517.
- 21. Liebig, P.A.; Heidemann, R.M.; Hensel, B.; Porter, D.A. A new approach to accelerate readout segmented EPI with compressed sensing. *Magn. Reson. Med.* **2020**, *84*, 321–326, doi:10.1002/mrm.28116.
- 22. Liu, K.; Xi, B.; Sun, H.; Wang, J.; Chen, C.; Wen, X.; Zhang, Y.; Zeng, M. The clinical feasibility of artificial intelligence-assisted compressed sensing single-shot fluid-attenuated inversion recovery (ACS-SS-FLAIR) for evaluation of uncooperative patients with brain diseases: comparison with the conventional T2-FLAIR with parallel imaging. *Acta Radiol.* **2022**, *64*, 1943–1949, doi:10.1177/02841851221139125.
- 23. Cristobal-Huerta, A.; Poot, D.H.J.; Vogel, M.W.; Krestin, G.P.; Hernandez-Tamames, J.A. Compressed Sensing 3D-GRASE for faster High-Resolution MRI. *Magn. Reson. Med.* **2019**, *82*, 984–999, doi:10.1002/mrm.27789.
- 24. Runge, V.M.; Richter, J.K.; Heverhagen, J.T. Simultaneous Multi-Slice a Concise Review Covering Major Applications in Clinical Practice. *MAGNETOM Flash* **2017**, *68*, 96–101.
- 25. Setsompop, K.; Cauley, S.F.; Wald, L.L. Advancing Diffusion MRI Using Simultaneous Multi-Slice Echo Planar Imaging. *MAGNETOM Flash* **2015**, *63*, 16–22.
- 26. Runge, V.M.; Richter, J.K.; Heverhagen, J.T. Speed in Clinical Magnetic Resonance. *Invest. Radiol.* **2017**, *52*, 1–17, doi:10.1097/RLI.00000000000330.

- 27. Schulz, J.; Marques, J.P.; Telgte, A. ter; Dorst, A. van; Leeuw, F.-E. de; Meijer, F.J.; Norris, D.G. Clinical application of Half Fourier Acquisition Single Shot Turbo Spin Echo (HASTE) imaging accelerated by simultaneous multi-slice acquisition. *Eur. J. Radiol.* 2018, 98, 200–206, doi:10.1016/j.ejrad.2017.11.022.
- 28. Cho, J.; Liao, C.; Tian, Q.; Zhang, Z.; Xu, J.; Lo, W.-C.; Poser, B.A.; Stenger, V.A.; Stockmann, J.; Setsompop, K.; et al. Highly accelerated EPI with wave encoding and multi-shot simultaneous multislice imaging. *Magn. Reson. Med.* **2022**, *88*, 1180–1197, doi:10.1002/mrm.29291.
- 29. Eliezer, M.; Vaussy, A.; Toupin, S.; Barbe, R.; Kannengiesser, S.; Stemmer, A.; Houdart, E. Iterative denoising accelerated 3D SPACE FLAIR sequence for brain MR imaging at 3T. *Diagn. Interv. Imaging* **2022**, 103, 13–20, doi:10.1016/j.diii.2021.09.004.
- 30. Quint, R.; Vaussy, A.; Stemmer, A.; Hautefort, C.; Houdart, E.; Eliezer, M. Iterative Denoising Accelerated 3D FLAIR Sequence for Hydrops MR Imaging at 3T. *AJNR Am. J. Neuroradiol.* **2023**, 44, 1064–1069, doi:10.3174/ajnr.A7953.
- 31. Granberg, T.; Uppman, M.; Hashim, F.; Cananau, C.; Nordin, L.E.; Shams, S.; Berglund, J.; Forslin, Y.; Aspelin, P.; Fredrikson, S.; et al. Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study. *AJNR Am. J. Neuroradiol.* **2016**, *37*, 1023–1029, doi:10.3174/ajnr.A4665.
- 32. Hagiwara, A.; Hori, M.; Yokoyama, K.; Takemura, M.; Andica, C.; Tabata, T.; Kamagata, K.; Suzuki, M.; Kumamaru, K.; Nakazawa, M.; et al. Synthetic MRI in the Detection of Multiple Sclerosis Plaques. *AJNR Am. J. Neuroradiol.* **2017**, *38*, 257–263, doi:10.3174/ajnr.A5012.
- 33. Hagiwara, A.; Otsuka, Y.; Hori, M.; Tachibana, Y.; Yokoyama, K.; Fujita, S.; Andica, C.; Kamagata, K.; Irie, R.; Koshino, S.; et al. Improving the Quality of Synthetic FLAIR Images with Deep Learning Using a Conditional Generative Adversarial Network for Pixel-by-Pixel Image Translation. *AJNR Am. J. Neuroradiol.* **2019**, 40, 224–230, doi:10.3174/ajnr.A5927.
- 34. Ryu, K.; Baek, H.; Cho, S.; Ha, J.; Kim, T.; Hwang, M. Clinical feasibility of 1-min ultrafast brain MRI compared with routine brain MRI using synthetic MRI: a single center pilot study. *J. Neurol.* **2019**, 266, 431–439, doi:10.1007/s00415-018-9149-4.
- 35. Wang, F.; Dong, Z.; Reese, T.G.; Bilgic, B.; Manhard, M.K.; Chen, J.; Polimeni, J.R.; Wald, L.L.; Setsompop, K. Echo planar time-resolved imaging (EPTI). *Magn. Reson. Med.* **2019**, *81*, 3599–3615, doi:10.1002/mrm.27673.
- 36. Wang, F.; Dong, Z.; Reese, T.G.; Rosen, B.; Wald, L.L.; Setsompop, K. 3D Echo Planar Time-resolved Imaging (3D-EPTI) for ultrafast multi-parametric quantitative MRI. *Neuroimage* **2022**, 250, 118963:1-118963:12, doi:10.1016/j.neuroimage.2022.118963.
- 37. Kerleroux, B.; Kober, T.; Hilbert, T.; Serru, M.; Philippe, J.; Sirinelli, D.; Morel, B. Clinical equivalence assessment of T2 synthesized pediatric brain magnetic resonance imaging. *Journal of Neuroradiology* **2019**, 46, 130–135, doi:10.1016/j.neurad.2018.04.003.
- 38. Gruenebach, N.; Abello Mercado, M.A.; Grauhan, N.F.; Sanner, A.; Kronfeld, A.; Groppa, S.; Schoeffling, V.I.; Hilbert, T.; Brockmann, M.A.; Othman, A.E. Clinical feasibility and validation of the accelerated T2 mapping sequence GRAPPATINI in brain imaging. *Heliyon* **2023**, *9*, e15064:1-e15064:9, doi:10.1016/j.heliyon.2023.e15064.
- 39. Lang, M.; Clifford, B.; Lo, W.-C.; Applewhite, B.P.; Tabari, A.; Filho, Augusto Lio M Goncalves; Hosseini, Z.; Longo, M.G.F.; Cauley, S.F.; Setsompop, K.; et al. Clinical Evaluation of a 2-Minute Ultrafast Brain MR Protocol for Evaluation of Acute Pathology in the Emergency and Inpatient Settings. *AJNR Am. J. Neuroradiol.* **2024**, *45*, 379–385, doi:10.3174/ajnr.A8143.
- 40. Altmann, S.; Grauhan, N.F.; Brockstedt, L.; Kondova, M.; Schmidtmann, I.; Paul, R.; Clifford, B.; Feiweier, T.; Hosseini, Z.; Uphaus, T.; et al. Ultrafast Brain MRI with Deep Learning Reconstruction for Suspected Acute Ischemic Stroke. *Radiology* **2024**, *310*, e231938:1-e231938:9, doi:10.1148/radiol.231938.
- 41. Verclytte, S.; Gnanih, R.; Verdun, S.; Feiweier, T.; Clifford, B.; Ambarki, K.; Pasquini, M.; Ding, J. Ultrafast MRI using deep learning echoplanar imaging for a comprehensive assessment of acute ischemic stroke. *Eur. Radiol.* **2023**, *33*, 3715–3725, doi:10.1007/s00330-023-09508-0.
- 42. Altmann, S.; Abello Mercado, M.A.; Brockstedt, L.; Kronfeld, A.; Clifford, B.; Feiweier, T.; Uphaus, T.; Groppa, S.; Brockmann, M.A.; Othman, A.E. Ultrafast Brain MRI Protocol at 1.5 T Using Deep Learning and Multi-shot EPI. *Acad. Radiol.* **2023**, *30*, 2988–2998, doi:10.1016/j.acra.2023.04.019.
- 43. Clifford, B.; Conklin, J.; Huang, S.Y.; Feiweier, T.; Hosseini, Z.; Gonçalves Filho, A.L.M.; Tabari, A.; Demir, S.; Lo, W.-C.; Longo, M.G.F.; et al. An artificial intelligence-accelerated 2-minute multi-shot echo planar imaging protocol for comprehensive high-quality clinical brain imaging. *Magn. Reson. Med.* **2022**, *87*, 2453–2463, doi:10.1002/mrm.29117.
- 44. Clifford, B.; Conklin, J.; Huang, S.; Feiweier, T.; Hosseini, Z.; Gonçalves Filho, A.L.M.; Tabari, A.; Demir, S.; Lo, W.-C.; Figueiro Longo, M.G.; et al. Clinical evaluation of an AI-accelerated two-minute multi-shot

- EPI protocol for comprehensive high-quality brain imaging. *Proceedings of the ISMRM & SMRT Annual Meeting & Exhibition, Virtual Meeting, 15-20 May 2021.*
- 45. Conklin, J.; Clifford, B.; Bollmann, S.; Lo, W.-C.; Bilgic, B.; Cauley, S.; Setsompop, K.; Feiweier, T.; Kirsch, J.; Gonzalez, R.; et al. A comprehensive multi-shot EPI protocol for high-quality clinical brain imaging in 3 minutes. *Proceedings of the ISMRM & SMRT Annual Meeting & Exhibition, Virtual Meeting*, 08-14 August 2020.
- 46. Tabari, A.; Clifford, B.; Gonçalves Filho, A.L.M.; Hosseini, Z.; Feiweier, T.; Lo, W.-C.; Figueiro Longo, M.G.; Setsompop, K.; Bilgic, B.; Rapalino, O.; et al. Ultrafast Brain Imaging with Deep Learning Multi-Shot EPI: Preliminary Clinical Evaluation. *MAGNETOM Flash* **2021**, *79*, 66–70.
- 47. Skare, S.; Sprenger, T.; Norbeck, O.; Rydén, H.; Blomberg, L.; Avventi, E.; Engström, M. A 1-minute full brain MR exam using a multicontrast EPI sequence. *Magn. Reson. Med.* **2018**, *79*, 3045–3054, doi:10.1002/mrm.26974.
- 48. Sprenger, T.; Kits, A.; Norbeck, O.; Niekerk, A. van; Berglund, J.; Rydén, H.; Avventi, E.; Skare, S. NeuroMix—A single-scan brain exam. *Magn. Reson. Med.* **2021**, *87*, 2178–2193, doi:10.1002/mrm.29120.
- 49. Delgado, A.F.; Kits, A.; Bystam, J.; Kaijser, M.; Skorpil, M.; Sprenger, T.; Skare, S. Diagnostic performance of a new multicontrast one-minute full brain exam (EPIMix) in neuroradiology: A prospective study. *J. Magn. Reson. Imaging* **2019**, *50*, 1824–1833, doi:10.1002/jmri.26742.
- 50. Ryu, K.H.; Baek, H.; Skare, S.; Moon, J.I.; Choi, B.H.; Park, S.E.; Ha, J.Y.; Kim, T.B.; Hwang, M.; Sprenger, T. Clinical Experience of 1-Minute Brain MRI Using a Multicontrast EPI Sequence in a Different Scan Environment. *AJNR Am. J. Neuroradiol.* **2020**, *41*, 424–429, doi:10.3174/ajnr.A6427.
- 51. Kits, A.; Luca, F.; Kolloch, J.; Müller, S.; Mazya, M.; Skare, S.; Delgado, A.F. One-Minute Multi-contrast Echo Planar Brain MRI in Ischemic Stroke: A Retrospective Observational Study of Diagnostic Performance. *J. Magn. Reson. Imaging* **2021**, *54*, 1088–1095, doi:10.1002/jmri.27641.
- 52. Burén, S.; Kits, A.; Lönn, L.; Luca, F.; Sprenger, T.; Skare, S.; Delgado, A.F. A 78 Seconds Complete Brain MRI Examination in Ischemic Stroke: A Prospective Cohort Study. *J. Magn. Reson. Imaging* **2022**, *56*, 884–892, doi:10.1002/jmri.28107.
- 53. Chung, M.S.; Lee, J.Y.; Jung, S.C.; Baek, S.; Shim, W.H.; Park, J.E.; Kim, H.S.; Choi, C.G.; Kim, S.J.; Lee, D.H.; et al. Reliability of fast magnetic resonance imaging for acute ischemic stroke patients using a 1.5-T scanner. *Eur. Radiol.* **2019**, 29, 2641–2650, doi:10.1007/s00330-018-5812-5.
- 54. Ha, J.Y.; Baek, H.J.; Ryu, K.H.; Choi, B.H.; Moon, J.I.; Park, S.E.; Kim, T.B. One-Minute Ultrafast Brain MRI With Full Basic Sequences: Can It Be a Promising Way Forward for Pediatric Neuroimaging? *AJR Am. J. Roentgenol.* **2020**, *215*, 198–205, doi:10.2214/AJR.19.22378.
- 55. Meshksar, A.; Villablanca, J.P.; Khan, R.; Carmody, R.; Coull, B.; Nael, K. Role of EPI-FLAIR in patients with acute stroke: a comparative analysis with FLAIR. *AJNR Am. J. Neuroradiol.* **2014**, *35*, 878–883, doi:10.3174/ajnr.A3786.
- Nael, K.; Khan, R.; Choudhary, G.; Meshksar, A.; Villablanca, P.; Tay, J.; Drake, K.; Coull, B.M.; Kidwell, C.S. Six-minute magnetic resonance imaging protocol for evaluation of acute ischemic stroke: pushing the boundaries. *Stroke* 2014, 45, 1985–1991, doi:10.1161/STROKEAHA.114.005305.
- 57. Traboulsee, A.; Simon, J.H.; Stone, L.; Fisher, E.; Jones, D.E.; Malhotra, A.; Newsome, S.D.; Oh, J.; Reich, D.S.; Richert, N.; et al. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. *AJNR Am. J. Neuroradiol.* **2016**, *37*, 394–401, doi:10.3174/ajnr.A4539.
- 58. Tawfik, A.I.; Kamr, W.H. Diagnostic value of 3D-FLAIR magnetic resonance sequence in detection of white matter brain lesions in multiple sclerosis. *Egypt. J. Radiol. Nucl. Med.* **2020**, *51*, 127:1-127:9, doi:10.1186/s43055-020-00247-6.
- 59. Hammernik, K.; Schlemper, J.; Qin, C.; Duan, J.; Summers, R.M.; Rueckert, D. Σ-net: Systematic Evaluation of Iterative Deep Neural Networks for Fast Parallel MR Image Reconstruction, 2019, arXiv (1912.09278v1). Available online: https://doi.org/10.48550/arXiv.1912.09278 (accessed on 14 June 2024).
- 60. Uecker, M.; Lai, P.; Murphy, M.J.; Virtue, P.; Elad, M.; Pauly, J.M.; Vasanawala, S.S.; Lustig, M. ESPIRiT An Eigenvalue Approach to Autocalibrating Parallel MRI: Where SENSE meets GRAPPA. *Magn. Reson. Med.* **2014**, *71*, 990–1001, doi:10.1002/mrm.24751.
- 61. Zhang, T.; Pauly, J.M.; Vasanawala, S.S.; Lustig, M. Coil compression for accelerated imaging with Cartesian sampling. *Magn. Reson. Med.* **2013**, *69*, 571–582, doi:10.1002/mrm.24267.
- 62. Demir, S.; Clifford, B.; Lo, W.-C.; Tabari, A.; Gonçalves Filho, A.L.M.; Lang, M.; Cauley, S.F.; Setsompop, K.; Bilgic, B.; Lev, M.H.; et al. Optimization of magnetization transfer contrast for EPI FLAIR brain imaging. *Magn. Reson. Med.* **2022**, *87*, 2380–2387, doi:10.1002/mrm.29141.
- 63. Jezzard, P.; Balaban, R.S. Correction for geometric distortion in echo planar images from B0 field variations. *Magn. Reson. Med.* **1995**, *34*, 65–73, doi:10.1002/mrm.1910340111.

- 64. Grauhan, N.F.; Grünebach, N.; Brockstedt, L.; Sanner, A.; Feiweier, T.; Schöffling, V.; Brockmann, M.A.; Othman, A.E. Reduction of Distortion Artifacts in Brain MRI Using a Field Map-based Correction Technique in Diffusion-weighted Imaging: A Prospective Study. *Clin. Neuroradiol.* **2024**, *34*, 85–91, doi:10.1007/s00062-023-01338-3.
- 65. Tintoré, M.; Rovira, A.; Martínez, M.J.; Rio, J.; Díaz-Villoslada, P.; Brieva, L.; Borrás, C.; Grivé, E.; Capellades, J.; Montalban, X. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. *AJNR Am. J. Neuroradiol.* **2000**, 21, 702–706.
- 66. Bender, R.; Lange, S.; Ziegler, A. Multiples Testen. *Dtsch. Med. Wochenschr.* **2007**, 132, e26-e29, doi:10.1055/s-2007-959035.
- 67. Noyes, K.; Weinstock-Guttman, B. Impact of diagnosis and early treatment on the course of multiple sclerosis. *Am. J. Manag. Care* **2013**, *19*, s321-s331.
- 68. Cohan, S.; Chen, C.; Baraban, E.; Stuchiner, T.; Grote, L. MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort. *BMC Neurol.* **2016**, *16*, 184, doi:10.1186/s12883-016-0699-8.
- 69. Eran, A.; García, M.; Malouf, R.; Bosak, N.; Wagner, R.; Ganelin-Cohen, E.; Artsy, E.; Shifrin, A.; Rozenberg, A. MRI in predicting conversion to multiple sclerosis within 1 year. *Brain Behav.* **2018**, *8*, e01042:1-e01042:6, doi:10.1002/brb3.1042.
- 70. Sutherland, G.; Russell, N.; Gibbard, R.; Dobrescu, A. *The Value of Radiology, Part II*, Ottawa: The Conference Board of Canada, 2019.
- 71. Nynatten, L. van; Gershon, A. Radiology wait times: Impact on Patient Care and Potential Solutions. *Univ. West. Ont. Med. J.* **2017**, *86*, 65–66, doi:10.5206/uwomj.v86i2.2048.
- 72. Sambeek, J.R. van; Joustra, P.E.; Das, S.F.; Bakker, P.J.; Maas, M. Reducing MRI access times by tackling the appointment-scheduling strategy. *BMJ Qual. Saf.* **2011**, 20, 1075–1080, doi:10.1136/bmjqs.2010.049643.
- 73. Nuti, S.; Vainieri, M. Managing waiting times in diagnostic medical imaging. *BMJ Open* **2012**, 2, e001255:1-e001255:10, doi:10.1136/bmjopen-2012-001255.
- 74. Biloglav, Z.; Medaković, P.; Buljević, J.; Žuvela, F.; Padjen, I.; Vrkić, D.; Ćurić, J. The analysis of waiting time and utilization of computed tomography and magnetic resonance imaging in Croatia: a nationwide survey. *Croat. Med. J.* **2020**, *61*, 538–546, doi:10.3325/cmj.2020.61.538.
- 75. Boldor, N.; Vaknin, S.; Myers, V.; Hakak, N.; Somekh, M.; Wilf-Miron, R.; Luxenburg, O. Reforming the MRI system: the Israeli National Program to shorten waiting times and increase efficiency. *Isr. J. Health Policy Res.* **2021**, *10*, 57:1-57:8, doi:10.1186/s13584-021-00493-7.
- 76. Henkelman, R.M.; Stanisz, G.J.; Graham, S.J. Magnetization transfer in MRI: a review. *NMR Biomed.* **2001**, 14, 57–64, doi:10.1002/nbm.683.
- 77. Deshmane, A.; Gulani, V.; Griswold, M.A.; Seiberlich, N. Parallel MR imaging. *J. Magn. Reson. Imaging* **2012**, 36, 55–72, doi:10.1002/jmri.23639.
- 78. Aja-Fernández, S.; Vegas-Sánchez-Ferrero, G.; Tristán-Vega, A. Noise estimation in parallel MRI: GRAPPA and SENSE. *Magn. Reson. Imaging* **2014**, *32*, 281–290, doi:10.1016/j.mri.2013.12.001.
- 79. Breuer, F.A.; Kannengiesser, S.A.; Blaimer, M.; Seiberlich, N.; Jakob, P.M.; Griswold, M.A. General formulation for quantitative G-factor calculation in GRAPPA reconstructions. *Magn. Reson. Med.* **2009**, *62*, 739–746, doi:10.1002/mrm.22066.
- 80. Bernstein, M.A.; King, K.F.; Zhou, X.J. *Handbook of MRI Pulse Sequences*; Elsevier Academic Press: Amsterdam, 2004, pp. 732-734, ISBN 978-0-12-092861-3.
- 81. Schenck, J.F. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. *Med. Phys.* **1996**, 23, 815–850, doi:10.1118/1.597854.
- 82. Phalke, V.V.; Gujar, S.; Quint, D.J. Comparison of 3.0 T versus 1.5 T MR: imaging of the spine. *Neuroimaging Clin. N. Am.* **2006**, *16*, 241-248, doi:10.1016/j.nic.2006.02.005.
- 83. Alvarez-Linera, J. 3T MRI: advances in brain imaging. *Eur. J. Radiol.* **2008**, *67*, 415–426, doi:10.1016/j.ejrad.2008.02.045.
- 84. Stadler, A.; Schima, W.; Ba-Ssalamah, A.; Kettenbach, J.; Eisenhuber, E. Artifacts in body MR imaging: Their appearance and how to eliminate them. *Eur. Radiol.* **2007**, *17*, 1242–1255, doi:10.1007/s00330-006-0470-4.
- 85. Arena, L.; Morehouse, H.T.; Safir, J. MR imaging artifacts that simulate disease: how to recognize and eliminate them. *Radiographics* **1995**, *15*, 1373–1394, doi:10.1148/radiographics.15.6.8577963.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.